Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake

Abstract

The present invention relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, by administering petrelintide at a high dose. The invention also relates to a method for treating overweight, obesity, diabetes and / or related disorders, and / or for reducing body weight, in a human female subject, by administering a non-incretin peptide hormone.

Description

[0001] 208 METHOD FIELD OF THE INVENTION The present invention relates to a method for treating overweight, obesity, diabetes and / or 5 related disorders, and / or for reducing body weight, by administering petrelintide at a high dose. The invention also relates to a method for treating overweight, obesity, diabetes and / orrelated disorders, and / or for reducing body weight, in a human female subject, byadministering a non-incretin peptide hormone. 10 BACKGROUND TO THE INVENTION Obesity is a currently a significant public health issue across much of the developed world and is correlated with the development of several serious conditions, such as cardiovascular disease, type 2 diabetes, sleep apnoea, and certain cancers. The standard treatment for obesity is lifestyle intervention, including the reduction of energy intake and the increase of 15 exercise. However, while such interventions can achieve temporary success, it is often challenging for patients to sustain such lifestyle changes over a long period such that the weight loss achieved is permanent. Amylin is a peptide hormone that has been implicated in various metabolic diseases and20 disorders. Native human amylin is a 37-amino acid peptide having the sequence: Hy-KC()NTATC()ATQRLANFLVHSSNNFGAILSSTNVGSNTY-NH2 (SEQ ID NO: 1) wherein Hy- at the N-terminus designates a hydrogen atom, corresponding to the presenceof a free amino group on the N-terminal amino acid residue (i.e. the lysine (K) residue at25 sequence position number 1 in the sequence shown above), wherein -NH2 at the C-terminusindicates that the C-terminal carboxyl group is in the amide form, and wherein theparentheses ()and 7 indicate the presence of an intramolecular disulphide bridge between the two Cys residues. 30 Amylin may be beneficial in treating metabolic disorders such as diabetes and / or obesity. Amylin is believed to regulate gastric emptying, and to suppress glucagon secretion and food intake, thereby regulating the rate of glucose release to the circulation. Amylin appears to complement the actions of insulin. Compared to healthy adults, type 1 diabetes patients 35 have no circulating amylin, and type 2 diabetes patients exhibit reduced postprandial amylin concentrations. 1 208 WO 2018 / 046719 A1 describes amylin analogues having, inter alia, a lactam bridge insteadof a disulphide bridge, N-methylated residues, and a deletion corresponding to the residues Asn21 and Asn22 of native human amylin. Such analogues have considerably lowertendency towards fibrillation than native amylin, while also having higher potency than other 5 known amylin analogues. SUMMARY OF THE INVENTION Broadly, the present invention relates to a method of reducing body weight using an amylinanalogue, petrelintide. 10 More specifically, the present invention relates to a method of reducing body weight using petrelintide at a high dose. Petrelintide has been surprisingly found to exhibit a favourableratio of exposure to adverse events. That is, higher doses of petrelintide do not lead to increased adverse events, particularly gastrointestinal adverse events. This advantageously15 allows petrelintide to be administered at higher doses to subjects who would not otherwise be willing or able to take a weight-loss drug at such a dose due to adverse effects, and means that subjects taking petrelintide may have a better quality of life than subjects using other weight-loss drugs with adverse effects.20 In this respect, gastrointestinal adverse disorders are well known for obesity drugs such assemaglutide (GLP-1 analogue) and cagrilintide (amylin / calcitonin agonist analogue). Cagrilintide is being developed by Novo Nordisk (Bagsværd, Denmark) for weight management. In a 26-week, phase 2 dose-finding trial of once-weekly doses of up to 4.5 mg cagrilintide (including a dose escalation period of up to 6 weeks), gastrointestinal disorders 25 and administration-site reactions were the most frequent adverse events. More participants receiving cagrilintide (0.3 4.5 mg) had gastrointestinal adverse events compared withplacebo (41% 63% vs 32%), primarily nausea (20% 47% depending on dose vs 18%).The present inventor has surprisingly found that it is possible to increase the exposure of 30 petrelintide by approximately 10-fold without decreasing the safety profile in terms of adverse events compared to lower exposures of petrelintide. In other words, though exposure to petrelintide increases, adverse events (such as nausea and vomiting) do not increase further. Thus, it has been surprisingly found that petrelintide exhibits a favourableratio of exposure to adverse events. 35 Thus, it was surprisingly found that it is possible to administer petrelintide at high dosages ofmore than 2.4 mg, for example up to 9.0 mg, such as up to 10.0 mg, once weekly, while2 208 achieving improved weight loss without decreasing the safety profile, includinggastrointestinal adverse events, compared to lower doses of petrelintide. This is shown inthe Examples herein. In particular, Tables 10 and 11a show that the number of participantsreporting gastrointestinal adverse events was lower / did not increase at high doses (2.4 mg 5 and above see Example 3) compared to low doses (less than 2.4 mg see Example 1 and 2), despite the highest dose being a 10-fold increase in exposure compared to the low dose.In other words, as shown in the below examples, it was demonstrated that the claimed once weekly amounts of petrelintide provide greater body weight reduction than lower amounts.10 However, this is not associated with a corresponding increase in participants reportinggastrointestinal adverse disorders, which would have been expected. The data presented in the application as filed shows that the doses used have a greater benefit-to-risk ratio than lower doses because the ratio between body weight reduction and participants reportinggastrointestinal adverse events is greater at the higher dose than the lower doses. Due to15 this unexpectedly good ratio between body weight reduction and gastrointestinal adverseevents it is possible to dose petrelintide at higher maintenance doses of 2.4 mg or greater without risking patient safety. Accordingly, the invention provides a method of treating one or more disease or disorder20 selected from overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnoea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes (e.g. type 2 diabetes), pre-diabetes or metabolic syndrome, or of reducing bodyweight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction25 long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The invention provides a method of treating overweight, overweight in the presence of at30 least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the35 subject about once weekly at a dose of 4.8 mg or more. 3 208 The invention provides a method of treating overweight, overweight in the presence of atleast one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, 5reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of 5 mg or more. The invention provides a method of treating overweight, overweight in the presence of at10 least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the15 subject about once weekly at a dose of 6.0 mg or more. The invention provides a method of treating overweight, overweight in the presence of atleast one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body20 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of 7.0 mg or more.25 The invention provides a method of treating overweight, overweight in the presence of atleast one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method30 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject about once weekly at a dose of 9.0 mg or more. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use in a method of treating overweight, overweight in the presence of at least one weight-related35 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a4 208 pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg. In some embodiments, the dose is more than 6.0 mg. In some embodiments, the dose is5 more than 7.0 mg. In some embodiments, the dose is at most 10.0 mg. In some embodiments, the dose is at most 9.0 mg. 10 In some embodiments, the dose is more than 4.6 mg and at most 9.0 mg. In some embodiments, the dose is from 4.8 mg to 9.0 mg.In some embodiments, the dose is more than 6.0 mg and at most 9.0 mg. In some embodiments, the dose is from 6.0 mg to 9.0 mg.In some embodiments, the dose is more than 7.0 mg and at most 9.0 mg.15 In some embodiments, the dose is from 7.0 mg to 9.0 mg.In some embodiments, the dose is 4.8 mg. In some embodiments, the dose is 5.0 mg. In some embodiments, the dose is 6.0 mg. In some embodiments, the dose is 7.0 mg. 20 In some embodiments, the dose is 9.0 mg. Additionally, the data presented herein indicate that female subjects show greater treatment response to petrelintide than men. In particular, Figure 8 and Tables 12, 13 and 14 inExample 4 herein show that women administered petrelintide exhibit greater reductions in25 body weight and waist circumference than men without experiencing a greater number orseverity of adverse events. Thus, the present application shows for the first time that female subjects exhibit a greater treatment response (e.g -30 peptide hormone. Iandstimulate insulin release to decrease blood glucose levels. Examples of incretin hormonesinclude glucagon-like peptide-1 (GLP-1) and its analogues, such as semaglutide, and gastric35 inhibitory polypeptide (GIP) and its analogues. The GLP-1 / GIP dual agonist tirzepatide isthus another example of an incretin hormone. 5 208 On the other hand, amylin is secreted from the pancreas, rather than the gut, and regulates glucagon secretion and gastric emptying. Therefore, amylin and its analogues, such as petrelintide, are not considered incretins. 5 It was not previously known that a non-incretin peptide hormone, such as amylin, could be more effective in reducing body weight in females than in males. Hence, the present application is the first demonstration of superior body weight reduction of women administered a non-incretin peptide hormone. Furthermore, this greater extent of body weight reduction is, however, not associated with increased occurrence or severity of10 adverse events (i.e., side effects) of the non-incretin peptide hormone, such as nausea andvomiting. That is, whilst women administered petrelintide lose more body weight than men, they do not experience more frequent or severe side-effects than men. These findingssurprisingly indicate that non-incretin hormones may be a particularly effective means fortreating obesity and related diseases (such as diabetes and diseases or comorbidities linked15 to overweight, obesity or diabetes, as described herein) in women. Furthermore, women administered a higher dose of petrelintide exhibited a greater loss of body weight compared to men than women administered a lower dose of petrelintide (see Table 13 herein). In other words, both men and women lost weight when administered 20 petrelintide, and this weight loss was dose-dependent (i.e., the higher the dose of petrelintide, the greater the weight loss). However, not only did women lose proportionally more weight than men when administered petrelintide (at all doses), but also the higher the dose of petrelintide, the greater the difference between men and women. These data may suggest that women are more responsive than men to treatment with a non-incretin peptide25 hormone. Accordingly, the invention provides a method of treating overweight, overweight in thepresence of at least one weight-related comorbid condition, obesity or morbid obesity,diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight,30 reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in ahuman female subject, the method comprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject.35 The invention also provides a non-incretin peptide hormone or a pharmaceuticallyacceptable salt thereof for use in a method of treating overweight, overweight in thepresence of at least one weight-related comorbid condition, obesity or morbid obesity,6 208 diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight,reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in ahuman female subject, the method comprising administering the non-incretin peptide5 hormone or a pharmaceutically acceptable salt thereof to the human female subject. In some embodiments, the non-incretin peptide hormone is an amylin analogue.Thus, the invention provides a method of treating overweight, overweight in the presence of10 at least one weight-related comorbid condition, obesity or morbid obesity, diabetes, or adisease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a humanfemale subject, the method comprising administering an amylin analogue or a15 pharmaceutically acceptable salt thereof to the female subject.The invention also provides an amylin analogue or a pharmaceutically acceptable saltthereof for use in a method of treating overweight, overweight in the presence of at least oneweight-related comorbid condition, obesity or morbid obesity, diabetes, or a disease linked to20 overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering the amylin analogue or a pharmaceutically acceptable salt thereofto the human female subject. 25 In some embodiments, the non-incretin peptide hormone is petrelintide.Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity or morbid obesity, diabetes, or a30 disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a humanfemale subject, the method comprising administering petrelintide or a pharmaceuticallyacceptable salt thereof to the human female subject. 35 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related 7 208 comorbid condition, obesity or morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes, or of reducing body weight, reducing excess body weight, inhibitingweight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the method5 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thehuman female subject. BRIEF DESCRIPTION OF THE FIGURES Figure 1: Single ascending dose trial design 10 The single ascending dose (SAD) trial of Example 1 comprised 7 cohorts each consisting of 6 participants receiving petrelintide, and 2 participants receiving a placebo. Doses were administered subcutaneously. An additional cohort of identical composition (not shown) received an intravenous dose at 0.35 mg.15 Figure 2: Pharmacokinetic profiles are consistent between cohorts Pharmacokinetic profiles for each cohort are displayed. Individual measured petrelintideconcentration in the blood following single dose subcutaneous administration is shown (A) as well as the geometric mean for each cohort for up to 35 days (B) and for up to 7 days (C). Each cohort exhibits a consistent pharmacokinetic profile. Further, there is little within cohort 20 variability in exposure. Figure 3: Dose-dependent reduction in bodyweight A dose-dependent and sustained reduction in body weight is observed in human participants receiving a single dose of petrelintide. (A) Shows the change in body weight of the individual25 participants in each cohort. (B) Shows mean change in body weight and 95% confidencelevel. Figure 4: Multiple Ascending Dose trial design (part 1) The Multiple Ascending Dose (MAD, part 1) trial of Example 2 comprised 2 cohorts each30 consisting of 7 participants receiving petrelintide, and 3 participants receiving a placebo. Doses were administered subcutaneously. Figure 5: Weight loss Areduction in body weight is observed in human participants receiving multiple doses of35 petrelintide. Panels are (l-r) Placebo, Amylin 0.6 mg and Amylin 1.2 mg. Graphs show the individual participants (thin lines) and the mean (thick line) for each cohort.8 208 Figure 6: Multiple Ascending Dose trial design (part 2) The Multiple Ascending Dose (MAD) trial of Example 3 comprised 3 cohorts each consistingof 12 participants receiving petrelintide, and 4 participants receiving a placebo. Doses wereadministered subcutaneously. The star indicates the data-cut for Trial Safety Group5 decisions to dose escalate. Figure 7: MAD trial part 2: individual % change in body weight by gender Graphs show percentage change in body weight of individual male (grey lines) and female(black lines) participants in each cohort of the MAD trial part 2. Panels are: (top left)10 petrelintide 2.4 mg; (top right) petrelintide 4.8 mg; (bottom left) petrelintide 9.0 mg; (bottom right) Placebo. Figure 8: Change in weight (%) by sex The graph shows percentage change in body weight from baseline over 16 weeks of15 individual male (blue bars) and female (yellow bars) participants in each cohort of the MADtrial part 2. Panels are (from left to right): placebo; petrelintide 2.4 mg; petrelintide 4.8 mg;and petrelintide 9.0 mg.DETAILED DESCRIPTION OF THE INVENTION 20 Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry, described herein, are those well-known and commonly used in the25 art. All patents, published patent applications and non-patent publications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control. 30 Each embodiment of the invention described herein may be taken alone or in combination with one or more other embodiments of the invention. General definitions 35 Unless specified otherwise, the following definitions are provided for specific terms used in the present written description. All other terms will be understood as having a meaning that is common in the art as would be attributed to them by the person skilled in the art. 9 208 or component, or group of integers or components, but not the exclusion of any other integer 5 or component, or group of integers or components. otherwise. 10 Petrelintide Petrelintide is an acylated peptide molecule that agonises amylin receptors. Petrelintide was15 first described in the patent application published as WO 2018 / 046719 A1 (which isincorporated herein by reference), wherein petrelintide was referred to as Compound 35.Petrelintide has the following formula: [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-20 LSSTEVGSNT-Hyp-NH2 (SEQ ID NO: 2) wherein [19CD]-isoGlu is a 19-carboxynonadecanoyl group covalently attached to the alpha amino group of an iso-glutamic acid linker; an intramolecular lactam bridge is formed between the side chains of residues indicated by 25 Aad refers to 2-aminoadipic acid; Gly(Me) refers to N-methylglycine; Ile(Me) refers to N-methylisoleucine; and Hyp refers to 4-hydroxyproline. 30 The chemical structure of [19CD]-isoGlu- covalently attached to arginine is shown below: 10 208 Petrelintide is an amylin receptor agonist. In other words, petrelintide is capable of bindingto, and inducing signalling by, one or more receptors or receptor complexes regarded as physiological receptors for human amylin. These include the human calcitonin receptor 5 (hCT-R), as well as complexes comprising hCT-R and at least one of the human receptor activity modifying proteins designated hRAMP1, hRAMP2 and hRAMP3. Complexes between hCT-R and hRAMP1, hRAMP2 and hRAMP3 are designated hAMYR1, hAMYR2 and hAMYR3 (i.e. human amylin receptors 1, 2 and 3) respectively. Petrelintide has agonist activity at hAMYR1, hAMYR2 and hAMYR3 as described in WO 2018 / 046719 A1. Binding10 to a suitable receptor induces intracellular signalling, e.g. cyclic AMP production. In vivo,petrelintide has the biological activity of (inter alia) reducing food intake, promoting weight loss, and / or inhibiting or reducing weight gain. It may be employed for various therapeutic applications as described elsewhere in this specification and in WO 2018 / 046719 A1. 15 Petrelintide may be manufactured by standard synthetic methods. Thus, petrelintide may be synthesized by, e.g., methods comprising synthesizing the peptide by standard solid-phase or liquid-phase methodology, either stepwise or by fragment assembly, and optionally isolating and purifying the final peptide product. In this context, reference may be made to WO 98 / 11125 or, inter alia -Phase20 Synthetic Peptides, Gregory A. Grant (ed.), Oxford University Press (2nd edition, 2002). The method typically further comprises the step of forming an amidebond between the side chains at positions 2 and 7. In the case of solid phase synthesis, cyclisation may be performed in situ on the solid phase (e.g. resin), i.e. before removal of the peptide from the solid phase. Synthesis of dapiglutide is described in Example 1 of WO25 2018 / 046719 A1. Petrelintide as used in the invention may be in the form of a pharmaceutically acceptable salt. Thus, any reference herein to petrelintide encompasses pharmaceutically acceptable salts thereof. T pharmac indicates a salt which is not30 harmful to a subject to which the salt in question is administered. Examples of Sciences,17th edition. Ed. Alfonso R. Gennaro (Ed.), Mack Publishing Company, Easton, PA, U.S.A., 1985 and more recent editions, and in the Encyclopaedia of Pharmaceutical Technology. 35 In particular, the salt may be a chloride salt. In some embodiments, petrelintide may have the formula 11 208 ([19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT- Hyp-NH2), x(Cl) where x is 1.0-2.0. 5 Pharmaceutical compositions Petrelintide In some embodiments, petrelintide is formulated in a pharmaceutical composition. 10 Thus, the invention also provides methods as described herein comprising administering to a subject a pharmaceutical composition comprising petrelintide or a pharmaceuticallyacceptable salt thereof. The invention also provides a pharmaceutical composition comprising petrelintide or a15 pharmaceutically acceptable salt or solvate thereof, for use in a method as described herein. In some embodiments, the composition comprises a pharmaceutically acceptable carrier, excipient or vehicle.20 Petrelintide may be formulated as a pharmaceutical composition which is suited foradministration with or without storage, and which typically comprises a therapeuticallyeffective amount of petrelintide, together with a pharmaceutically acceptable carrier, excipient or vehicle. standard pharmaceutical carriers. Pharmaceutically acceptable carriers for therapeutic use 25 Company, Easton, PA, USA, 1985. In some embodiments, the pharmaceutical compositionis a stable aqueous liquid pharmaceutical composition (i.e. a stable aqueous liquid formulation). 30 Examples of stable aqueous liquid formulations comprising petrelintide are disclosed in WO2023 / 232781 A1 (which is incorporated herein by reference). Methods of treatment35 Generally, petrelintide is useful, inter alia, in the reduction of food intake, promotion of weight loss, and inhibition or reduction of weight gain. Petrelintide may therefore provide an attractive treatment option for, inter alia, obesity and metabolic diseases caused, 12 208 characterised by, or associated with, excess body weight. Treatment may be achieved, for example, by control of appetite, feeding, food intake, calorie intake and / or energy expenditure. 5 As a result, petrelintide may be used for treatment of a variety of conditions, diseases, or disorders in a subject, including, but not limited to, obesity and various obesity-related conditions, diseases, or disorders, such as diabetes (e.g. type 2 diabetes), hypertension, dyslipidemia, sleep apnea and cardiovascular disease. The subject may be affected by obesity accompanied by at least one weight-related co-morbid condition, such as diabetes 10 (e.g. type 2 diabetes), hypertension, dyslipidemia, sleep apnea and cardiovascular disease. It will be understood that the amylin analogues may thus be administered to subjects affected by conditions characterised by inadequate control of appetite or otherwise over- feeding, such as binge-eating disorder and Prader-Willi syndrome. It will be clear that the analogues can be used for treatment of combinations of the conditions described. 15 Effects of petrelintide on these conditions may be mediated in whole or in part via an effecton body weight, or may be independent thereof. 20 employed in the context of the invention refers to an approach for obtaining beneficial or 25 desired clinical results. For the purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilization of (i.e. not worsening of) state of disease, delay or slowing of disease progression, amelioration or palliation of disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" may also refer to 30 prolongation of survival compared to expected survival in the absence of treatment. "Treatment" is an intervention performed with the intention of arresting the development of, or altering the pathology of, a disorder. symptom of a disease, to any extent. For example, a very small reduction in a single symptom of the disease may be considered treatment. inhibition or35 reduction of an increase in pathology or symptoms (e.g. weight gain or hypoglycaemia) compared to the absence of treatment, and is not necessarily meant to imply complete cessation or cure of the relevant condition. 13 208 Treating obesity and obesity-related disorders The invention provides methods and medical uses of treating or preventing overweight, overweight in the presence of at least one weight-related comorbid condition, obesity,5 morbid obesity or a disease linked to overweight, obesity or morbid obesity in a subject.Thus, the invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a method of treating obesity as well as associated diseases, disorders and health conditions, including, but not limited to, morbid obesity, obesity prior to surgery, obesity- 10 induced type 2 diabetes, obesity-linked inflammation, obesity-linked gallbladder disease and obesity-induced sleep apnea and respiratory problems, cardiovascular disease, binge-eating disorder, Prader-Willi syndrome, degeneration of cartilage, osteoarthritis, and reproductive health complications of obesity or overweight such as infertility. 15 The invention also provides use of petrelintide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating obesity as well as associated diseases, disorders and health conditions, including, but not limited to, morbid obesity, obesity prior to surgery, obesity-linked inflammation, obesity-linked gallbladder disease and obesity-induced sleep apnea and respiratory problems, cardiovascular disease, binge-eating disorder, 20 Prader-Willi syndrome, degeneration of cartilage, osteoarthritis, and reproductive health complications of obesity or overweight such as infertility. The invention also provides a method of treating obesity as well as associated diseases, disorders and health conditions, including, but not limited to, morbid obesity, obesity prior to 25 surgery, obesity-linked inflammation, obesity-linked gallbladder disease and obesity-induced sleep apnea and respiratory problems, cardiovascular disease, binge-eating disorder, Prader-Willi syndrome, degeneration of cartilage, osteoarthritis, and reproductive health complications of obesity or overweight such as infertility in a subject, comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject. 30 The subject may be affected by obesity accompanied by at least one weight-related co- morbid condition, such as diabetes (e.g. type 2 diabetes), hypertension, dyslipidemia, sleep apnea and cardiovascular disease. 35 The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes in a subject, the method comprising administering14 208 petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide may be any dose described herein.Weight 5Weight is defined in the medical field by body mass index (BMI), which is calculated forhuman subjects by dividing the weight of the subject in kilograms by the square of the height of the subject in metres. ABMI of 18.5 kg / m2 to 24.9 kg / m2 corresponds to healthy weight.10 an overall body weight which is more than a healthy weight.desirable. A BMI of 25.0 kg / m2 to 29.9 kg / m2 corresponds to overweight.15 a medical condition characterized by excessive body fataccumulation, presenting a risk to health, according to the World Health Organization(WHO). A BMI of 30.0 kg / m2 to 39.9 kg / m2 corresponds to obese.The term form of obesity. In other words, a morbidly20 obese subject has extremely excessive body weight. A BMI of 40.0 or higher corresponds tomorbidly obese. yand morbid obesity together. In25 has a medical condition characterized by excess body weight, regardless of the severity ofthe condition. In this context, a BMI of 30.0 kg / m2 or higher / greater(class I) corresponds to a BMI of 30.0 kg / m2to 34.9 kg / m2, obesity (class II) (also referred to 30 o a BMI of 35.0 kg / m2to 39.9 kg / m2, and obesity (class III) .0 kg / m2or higher. Overweight in the presence of at least one weight-related comorbid condition The expression overweight in the presence of at least one weight-related comorbid35 associated with being overweight. To put it another way, it is well-known that being overweight (or obese) leads to further health complications (i.e., disease). Such a disease is 15 208 -weight-related comorbid conditionmay be described as being linked, to, associated with or caused by overweight. By reducing body weight, the methods and medical uses of the invention can treat overweight and thereby alleviate symptoms of the weight-related comorbid condition. 5 -related comorbid condition. That is, the subject is overweight and is suffering from at least one weight-related comorbid condition. 10 overweight in the presence of at least one weight-related comorbid -related herein. 15 In some embodiments, the disease is overweight in the presence of at least one weight- related comorbid condition. In some embodiments, the disease is overweight in the presence of a weight-related comorbid condition. In some embodiments, the disease is a comorbid condition or comorbidity associated with or20 caused by overweight. In some embodiments, the subject is overweight and has at least one weight-related comorbid condition. In some embodiments, the subject is overweight and has more than one weight-related 25 comorbid condition. In some embodiments, the subject is overweight and has multiple weight-related comorbid conditions. As described herein, a ght- 30 obesity or di -Hence, the at least one weight-related comorbid can be any of the weight-related comorbid conditions (i.e., any of the diseases linked to overweight, obesity, morbid obesity or 35 diabetes) described herein. 16 208 In some embodiments, the weight-related comorbid condition is selected from the groupconsisting of obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin 5 resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis (NASH), kidney failure, arteriosclerosis,macrovascular disease, microvascular disease, diabetic heart disease, diabetic 10 cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease and stroke. In some embodiments, the disease is overweight in the presence of a weight-related comorbid condition is selected from the group consisting of obesity-linked inflammation,15 obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, Alzhei -diabetes, insulin resistance syndrome, impaired glucosetolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia,20 hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis(NASH), kidney failure, arteriosclerosis, macrovascular disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease and stroke. 25 In some embodiments, the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin resistance syndrome, impaired glucose 30 tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis(NASH), kidney failure, arteriosclerosis, macrovascular disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, 35 coronary heart disease, peripheral artery disease and stroke. 17 208 Treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesityThe invention provides a method of treating overweight in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once 5weekly at a dose of 2.4 mg or more. The invention provides a method of treating overweightin a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The doseof petrelintide may be any dose described herein. The invention provides a method of treating overweight in a subject, the method comprising 10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. The invention provides a method of treating overweight in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. 15 The invention provides a method of treating overweight in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. The invention provides a method of treating overweight in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once20 weekly at a dose of 7.0 mg. The invention provides a method of treating overweight in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. 25 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable saltthereof may be any dose described herein. 30 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. The invention provides a method of treating overweight in the presence of at least one35 weight-related comorbid condition in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. 18 208 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. 5 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg. The invention provides a method of treating overweight in the presence of at least one10 weight-related comorbid condition in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. The invention provides a method of treating obesity in a subject, the method comprising 15 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. The invention provides a method of treating obesity in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose ofpetrelintide may be any dose described herein. 20 The invention provides a method of treating obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. The invention provides a method of treating obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once25 weekly at a dose of 5.0 mg. The invention provides a method of treating obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. The invention provides a method of treating obesity in a subject, the method comprising 30 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg. The invention provides a method of treating obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. 35 The invention provides a method of treating morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the 19 208 subject once weekly at a dose of 2.4 mg or more. The invention provides a method oftreating morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any5 dose described herein. The invention provides a method of treating morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. The invention provides a method of treating morbid obesity in a subject, the method 10 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. The invention provides a method of treating morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. 15 The invention provides a method of treating morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 7.0 mg.The invention provides a method of treating morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the20 subject once weekly at a dose of 9.0 mg. The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition obesity or morbid obesity in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof25 to the subject once weekly at a dose of 2.4 mg or more. The invention provides a method oftreating overweight, overweight in the presence of at least one weight-related comorbid condition obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt30 thereof may be any dose described herein. The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. 35 The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the20 208 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the5 method comprising administering petrelintide or a pharmaceutically acceptable salt thereofto the subject once weekly at a dose of 6.0 mg. The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof10 to the subject once weekly at a dose of 7.0 mg. The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. 15 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a20 pharmaceutically acceptable salt thereof may be any dose described herein. The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 4.8 mg. 25 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 5.0 mg. The invention provides a method of treating overweight in the presence of at least one30 weight-related comorbid condition, obesity or morbid obesity in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method35 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg. 21 208 The invention provides a method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. 5 The invention provides a method of treating obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. The invention provides a method oftreating obesity or morbid obesity in a subject, the method comprising administering 10 petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide may be any dose described herein.The invention provides a method of treating obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. 15 The invention provides a method of treating obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. The invention provides a method of treating obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof20 to the subject once weekly at a dose of 6.0 mg. The invention provides a method of treating obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg. The invention provides a method of treating obesity or morbid obesity in a subject, the 25 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. Diabetes The invention provides a method of treating diabetes in a subject, the method comprising 30 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more.The invention provides a method of treating diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of more than 2.4 mg.35 The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein. 22 208 Diabetes is a chronic metabolic disease characterized by elevated levels of blood glucosedue to an inability to produce or respond to insulin. Over time, elevated blood glucose lead to damage to organs and cells, such as the heart, blood vessels, eyes, kidneys and nerves. 5In some embodiments, the diabetes is type 2 diabetes. Type 2 diabetes occurs when thenbody becomes resistant to insulin or does not produce enough insulin. Type 2 diabetes is often associated with (i.e., occurs at the same time as) overweight or obesity. The invention provides a method of treating diabetes in a subject, the method comprising 10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. The invention provides a method of treating diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. 15 The invention provides a method of treating diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. The invention provides a method of treating diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once20 weekly at a dose of 7.0 mg. The invention provides a method of treating diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. 25 Disease linked to overweight, obesity or diabetes The invention also provides a method of treating a disease linked to overweight, obesity ordiabetes in a subject, the method comprising administering petrelintide or a pharmaceuticallyacceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. Theinvention also provides a method of treating a disease or comorbidity linked to overweight,30 obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be anydose described herein. 35 refers to any disease for which overweight, obesity or diabetes is a causative factor and / or which occurs at the same time as overweight, obesity or diabetes in a subject due to the overweight, obesity or23 208 diabetes .Thus, a may be considered a health-related complication of the underlying condition of being overweight or obese, or of sufferingfrom diabetes. 5 A disease linked to overweight, obesity or diabetes comorbidity is a disease associated with overweight, obesity (including morbid obesity) ordiabetes. In this regard, it is well-known that being overweight, obese, morbidly obese or diabetic leads to further health complications (i.e., disease). Such a disease is referred to as10 as comorbidi -words, the disease is a comorbidity of overweight, obesity (including morbid obesity) ordiabetes linked to overweight, obesity or diabetesoverweight, obesity, morbid obesity or diabetes15 It is well-known that being overweight or obese leads to further health complications (i.e., -related Hence, the expression may be used --20 obesity, morbid obesit . As such, the diseases and conditions described herein-related Thus, the invention provides a method of treating overweight, overweight in the presence of25 at least one weight-related comorbid condition, obesity, morbid obesity, diabetes or a weight-related comorbid condition, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject once30 weekly at a dose of 2.4 mg or more. The dose of petrelintide or a pharmaceuticallyacceptable salt thereof may be any dose described herein. The invention provides a method of treating overweight, overweight in the presence of atleast one weight-related comorbid condition, obesity, morbid obesity, diabetes or a weight-35 related comorbid condition in a subject, the method comprising administering petrelintide ora pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. 24 208 The invention provides a method of treating overweight, overweight in the presence of atleast one weight-related comorbid condition, obesity, morbid obesity, diabetes or a weight-related comorbid condition in a subject, the method comprising administering petrelintide ora pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than5 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein. The invention provides a method of treating a weight-related comorbid condition in a subject,10 the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. The invention provides a method of treating a weight-related comorbid condition in a subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. 15 The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein. The expression may be used interchangeably herein with . 20 In some embodiments, the disease linked to overweight, obesity or diabetes is selected from the group consisting of obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, - 25 diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholicfatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), kidney failure,arteriosclerosis, macrovascular disease, microvascular disease, diabetic heart disease, 30 diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease and stroke. In some embodiments, the weight-related comorbid condition is selected from the groupconsisting of obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced 35 type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with 25 208 elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis (NASH), kidney failure, arteriosclerosis,macrovascular disease, microvascular disease, diabetic heart disease, diabetic 5 cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease and stroke. Thus, the invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, obesity-10 linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic15 dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholicsteatohepatitis (NASH), kidney failure, arteriosclerosis, macrovascular disease,microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease or stroke in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable20 salt thereof to the subject once weekly at a dose of about 2.4 mg or more. Thus, the invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, 25 obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic30 steatohepatitis (NASH), kidney failure, arteriosclerosis, macrovascular disease,microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease or stroke in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. 35 26 208 In some embodiments, the method is a method of treating obesity-linked inflammation,obesity-induced sleep apnea, such as moderate to severe obstructive sleep apnea (OSA),obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis or infertility.5 In some embodiments, the method is a method of treating obesity-induced type 2 diabetes,, pre-diabetes, insulin resistance syndrome, impaired glucose tolerance(IGT), disease states associated with elevated blood glucose levels, metabolic disease,metabolic syndrome, hyperglycemia or hypertension.10 In some embodiments, the method is a method of treating obesity-linked gallbladderdisease, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis (NASH) or kidney failure.In some embodiments, the method is a method of treating arteriosclerosis, macrovascular15 disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heartfailure as a diabetic complication, coronary heart disease, peripheral artery disease orstroke. In some embodiments, the disease linked to overweight, obesity or diabetes is a disease20 linked to overweight or obesity. In some embodiments, the disease linked to overweight or obesity is obesity-linked inflammation, obesity-linked gallbladder disease, obesity-inducedtype 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, obesity- linked degeneration of cartilage, obesity-linked osteoarthritis or obesity-linked infertility.25 It is well-known that excessive weight, such as in obesity, is associated with poor cardiovascular health. Excessive body weight increases the risk of major adverse cardiovascular events (e.g., heart attack). Hence, in some embodiments, the method is a method for reducing the risk of a major30 adverse cardiovascular event. In some embodiments, the major adverse cardiovascular event is cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. In some embodiments, the method is a method for reducing the risk of a major adverse cardiovascular event (such as cardiovascular death, non-fatal myocardial infarction or non- 35 fatal stroke) in a subject, wherein the subject is overweight or obese and has a cardiovascular disease. 27 208 Metabolic disease and related disorders The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of prevention or treatment of type 2 diabetes, pre-diabetes, insulin resistance syndrome, impaired glucose tolerance 5 (IGT), disease states associated with elevated blood glucose levels, metabolic disease including metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis -alcoholic fatty liver disease (NAFLD), which itself includes non-alcoholic steatohepatitis (NASH)), kidney failure, arteriosclerosis (e.g.atherosclerosis), macrovascular disease, microvascular disease, diabetic heart disease 10 (including diabetic cardiomyopathy and heart failure as a diabetic complication), coronary heart disease, peripheral artery disease or stroke, and combinations thereof. The invention also provides use of petrelintide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of 15 diabetes, type 1 diabetes, type 2 diabetes, pre-diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease including metabolic syndrome, hyperglycemia, hypertension, -alcoholic fatty liver disease (NAFLD), which itself includes non-alcoholic steatohepatitis (NASH)), kidney failure,20 arteriosclerosis (e.g. atherosclerosis), macrovascular disease, microvascular disease, diabetic heart disease (including diabetic cardiomyopathy and heart failure as a diabetic complication), coronary heart disease, peripheral artery disease or stroke, and combinations thereof. 25 The invention also provides a method of prevention or treatment of diabetes, type 1 diabetes, type 2 diabetes, pre-diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease including metabolic syndrome, hyperglycemia, hypertension, -alcoholic fatty liver30 disease (NAFLD), which itself includes non-alcoholic steatohepatitis (NASH)), kidney failure,arteriosclerosis (e.g. atherosclerosis), macrovascular disease, microvascular disease, diabetic heart disease (including diabetic cardiomyopathy and heart failure as a diabetic complication), coronary heart disease, peripheral artery disease or stroke, and combinations thereof, in a subject, the method comprising administering petrelintide or a pharmaceutically 35 acceptable salt thereof to the subject. 28 208 In some embodiments, the subject suffers from metabolic syndrome. Metabolic syndrome is characterized by a group of metabolic risk factors in one person. They include abdominal obesity (excessive fat tissue around the abdominal internal organs), atherogenic dyslipidemia (blood fat disorders including high triglycerides, low HDL cholesterol and / or 5 high LDL cholesterol, which foster plaque build-up in artery walls), elevated blood pressure (hypertension), insulin resistance and glucose intolerance, prothrombotic state (e.g. high fibrinogen or plasminogen activator inhibitor-1 in the blood), and proinflammatory state (e.g., elevated C-reactive protein in the blood). 10 Individuals with metabolic syndrome are at increased risk of coronary heart disease and other diseases related to other manifestations of arteriosclerosis (e.g. stroke and peripheralvascular disease). The dominant underlying risk factor for this syndrome appears to be abdominal obesity.15 In some embodiments, the subject has diabetes. In some embodiments, the disease is type1 diabetes. In some embodiments, the disease is type 2 diabetes.Lowering LDL Petrelintide may also be useful in lowering circulating LDL levels and / or increasing HDL / LDL20 ratio. Therefore, the invention provides petrelintide or a pharmaceutically acceptable salt thereoffor use in a method of lowering circulating LDL levels and / or increasing HDL / LDL ratio. 25 The invention also provides use of petrelintide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for lowering circulating LDL levels and / or increasingHDL / LDL ratio. The invention further provides a method of lowering circulating LDL levels and / or increasing 30 HDL / LDL ratio in a subject, comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject. Prevention In some embodiments, the invention provides a method of preventing overweight,35 overweight in the presence of at least one weight-related comorbid condition, obesity,morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or ofreducing body weight, reducing excess body weight, inhibiting weight gain, maintaining 29 208 weight reduction long term, reducing food intake, reducing appetite, increasing satiety orpromoting weight loss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be5 any dose described herein. In some embodiments, the invention provides a method of preventing overweight,overweight in the presence of at least one weight-related comorbid condition, obesity,morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject,10 the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg. The dose ofpetrelintide may be any dose described herein. The invention provides a method of preventing a weight-related comorbid condition in a15 subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg. The dose ofpetrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein. 20 preventing the development of, or altering the pathology of, a condition, disease or disorder. purposes of this invention, beneficial or desired clinical results include, but are not limited to, prevention or slowing of symptoms, progression or development of a disease, whether 25 subject not yet afflicted with the disease or disorder in question. The t includes inhibiting or slowing the onset of disease relative to the absence of treatment, and is not necessarily meant to imply permanent prevention of the relevant disease, disorder or 30 invention may mean prevention of weight gain (i.e. inhibiting weight gain). In some No combination with GLP-1 / GLP-2 dual agonistIn some embodiments, petrelintide or the pharmaceutically acceptable salt thereof is not35 administered with a GLP-1 / GLP-2 dual agonist. In some embodiments, petrelintide or thepharmaceutically acceptable salt thereof is not administered in combination with a GLP- 1 / GLP-2 dual agonist.30 208 In some embodiments, petrelintide or the pharmaceutically acceptable salt thereof is not administered with dapiglutide. In some embodiments, petrelintide or the pharmaceuticallyacceptable salt thereof is not administered in combination with dapiglutide. 5 whilst undergoing a course of treatment with petrelintide (i.e., whilst the subject is receiving petrelintide once weekly, according to the dosage regimen of the present invention), theother GLP-1 / GLP-2 dual agonist, such as dapiglutide, is not administered to the subject. In10 other words, the GLP-1 / GLP-2 dual agonist, such as dapiglutide, is not administered to the subject for the whole period in which petrelintide is administered to the subject (i.e., the administration period, as described herein). Medical uses 15 The invention may also be expressed as a medical use. Thus, the invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a method of treating overweight, overweight in the presence of at least one weight- related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to20 overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of about 2.4 mg or more. The dose of petrelintide or a25 pharmaceutically acceptable salt thereof may be any dose described herein. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,30 obesity or diabetes, or of reducing body weight, reducing excess body weight, inhibitingweight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg. 35 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use in a method of treating overweight, overweight in the presence of at least one weight-related 31 208 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. The dose of petrelintide may be any dose described herein. 5 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use in a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a10 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than2.4 mg. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related15 comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein.20 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof25 may be any dose described herein. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating obesity, morbid obesity, diabetes, or a disease linked to obesity or diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically30 acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. The dose ofpetrelintide or a pharmaceutically acceptable salt may be any dose described herein. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating obesity, morbid obesity, diabetes, or a disease linked to obesity or35 diabetes in a subject, the method comprising administering petrelintide or a pharmaceuticallyacceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg.32 208 The invention also provides use of petrelintide or a pharmaceutically acceptable salt thereof in manufacture of a medicament for a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity,diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight,5 reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. The dose of petrelintidemay be any dose described herein. 10 The invention also provides use of petrelintide or a pharmaceutically acceptable salt thereof in manufacture of a medicament for a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity,diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight,15 reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg.20 The invention provides use of petrelintide or a pharmaceutically acceptable salt thereof inmanufacture of a medicament for a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity,diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the25 subject once weekly at a dose of 2.4 mg or more. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein.The invention provides use of petrelintide or a pharmaceutically acceptable salt thereof inmanufacture of a medicament for a method of treating overweight, overweight in the30 presence of at least one weight-related comorbid condition, obesity, morbid obesity,diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein.35 33 208 All embodiments of the methods of the invention described herein are embodiments of the invention when expressed as a medical use (i.e., as petrelintide for use in a method of the invention or use of petrelintide for manufacture of a medicament). 5 Medical uses specific doses The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a10 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than2.4 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related15 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 4.8 mgto 10.0 mg.20 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 4.8 mg25 to 9.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,30 obesity or diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 6.0 mgto 10.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a35 method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a 34 208 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 6.0 mgto 9.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a5 method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg ormore. 10 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a15 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg ormore. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related20 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg ormore.25 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.30 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a35 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg.35 208 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a subject, the method comprising administering petrelintide or a 5pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mgThe invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of more than 2.4 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related15 comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 4.8 mg to 10.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a20 method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 4.8 mg to 9.0 mg.25 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 6.0 mg to 10.0 mg. 30 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject once35 weekly at a dose of from 6.0 mg to 9.0 mg. 36 208 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject once5 weekly at a dose of 4.8 mg or more. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg or more. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related15 comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a20 method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg.25 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 9.0 mg. 30 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a35 dose of more than 2.4 mg. 37 208 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a5 dose of from 4.8 mg to 10.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administering10 petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of from 4.8 mg to 9.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid15 condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of from 6.0 mg to 10.0 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in a20 method of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of from 6.0 mg to 9.0 mg.25 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of 4.8 mg or more. 30 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a35 dose of 6.0 mg or more. 38 208 The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a5 dose of 4.8 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, the method comprising administering10 petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of 5 mg. The invention provides petrelintide or a pharmaceutically acceptable salt thereof for use in amethod of treating overweight in the presence of at least one weight-related comorbid15 condition, obesity or morbid obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of 6.0 mg. The invention provides petrelintide for use in a method of treating overweight in the presence20 of at least one weight-related comorbid condition, obesity or morbid obesity in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg. Methods of reducing body weight, reducing excess body weight, inhibiting weight25 gain, maintaining weight reduction long term and promoting weight lossThe invention provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject once30 weekly at a dose of 2.4 mg or more. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dose described herein.The invention also provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake,35 reducing appetite, increasing satiety or promoting weight loss in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 4.8 mg. 39 208 The invention also provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject, the method5 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 6.0 mg. The invention also provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake,10 reducing appetite, increasing satiety or promoting weight loss in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 9.0 mg. The invention also provides a method of reducing body weight, reducing excess body15 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 4.8 mg or more. 20 The invention also provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 6.0 mg or more. 25 The invention also provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the30 subject once weekly at a dose of more than 2.4 mg. In some embodiments, the invention provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term orpromoting weight loss in a subject, the method comprising administering petrelintide or a35 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg ormore. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be anydose described herein. 40 208 In some embodiments, the invention provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term orpromoting weight loss in a subject, the method comprising administering petrelintide or a 5pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.In some embodiments, the invention provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term orpromoting weight loss in a subject, the method comprising administering petrelintide or a10 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5 mg.In some embodiments, the invention provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term orpromoting weight loss in a subject, the method comprising administering petrelintide or a15 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg.In some embodiments, the invention provides a method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term orpromoting weight loss in a subject, the method comprising administering petrelintide or a20 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg.Reducing body weight In some embodiments, the invention provides a method of reducing body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the25 subject once weekly at a dose of 2.4 mg or more. In some embodiments, the inventionprovides a method of reducing body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable saltthereof may be any dose described herein.30 In some embodiments, the invention provides a method of reducing excess body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. In some embodiments, the inventionprovides a method of reducing excess body weight, the method comprising administering35 petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable saltthereof may be any dose described herein.41 208 embodiments, excess body weight is any portion of body weight which takes the subject above healthy weight (i.e., any body weight without which the subject would be of a healthy 5weight, rather than overweight, obese or morbidly obese). In other words, in someembodiments, excess body weight is any weight borne by the subject which makes them overweight, obese or morbidly obese. 18.5 kg / m2to 24.9 kg / m2corresponds to healthy weight, a BMI of 25.0 kg / m2to 29.9 kg / m210 corresponds to overweight, a BMI of 30.0 kg / m2 to 39.9 kg / m2 corresponds to obese, and aBMI of 40.0 or higher corresponds to morbidly obese.In some embodiments, excess body weight is any portion of body weight which takes the subject above over weight (i.e., any body weight without which the subject would be15 overweight, rather than obese or morbidly obese). In other words, in some embodiments,excess body weight is any weight borne by the subject which makes them obese or morbidlyobese. 20 efers to reducing that portion of body weight which is in excess (i.e., which renders the subject overweight, obese or morbidly obese). 25 The invention provides a method of reducing body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg.The invention provides a method of reducing body weight, the method comprising30 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg.The invention provides a method of reducing body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once35 weekly at a dose of 9.0 mg.42 208 The invention provides a method of reducing excess body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg.5 The invention provides a method of reducing excess body weight, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg.The invention provides a method of reducing excess body weight, the method comprising10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 9.0 mg.Inhibiting weight gain In some embodiments, the invention provides a method of inhibiting weight gain, the method15 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 2.4 mg or more. The invention provides a method of inhibiting weight gain, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once20 weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein. 25 The invention provides a method of inhibiting weight gain, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg. The invention provides a method of inhibiting weight gain, the method comprising30 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg. The invention provides a method of inhibiting weight gain, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once35 weekly at a dose of 9.0 mg. 43 208 Maintaining weight reduction long term In some embodiments, the invention provides a method of maintaining weight reduction long term, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more.5 In some embodiments, the invention provides a method of maintaining weight reduction long term, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg.10 The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein. enabling a subject who has lost weight to not regain the weight they have lost. It is well-known that it may be possible for a 15 subject to reduce their body weight through lifestyle changes (such as consuming a reduced calorie diet or increasing physical activity), but these lifestyle changes can be difficult to maintain, leading ultimately to the subject regaining the lost weight. Administration ofpetrelintide leads directly to weight reduction and can also assist the subject in maintaining the lifestyle changes that also lead to weight reduction, thereby maintaining weight reduction 20 long term. may mean the entire administration period (i.e., the total period in which petrelintide is administered to the subject, as described herein).25 such as at least 2 years, at least 3 years, at least 4 years, at least 5 years, at least 6 years,at least 7 years, at least 8 years, at least 9 years,may mean the rest of 30 reduction. In some embodiments, the subject does not gain weight. In some embodiments, the method is a method of no weight gain. 35 44 208 In some embodiments, the invention provides a method of maintaining weight reduction long term, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.5 In some embodiments, the invention provides a method of maintaining weight reduction long term, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5 mg.In some embodiments, the invention provides a method of maintaining weight reduction long 10 term, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg.In some embodiments, the invention provides a method of maintaining weight reduction long term, the method comprising administering petrelintide or a pharmaceutically acceptable salt15 thereof to the subject once weekly at a dose of 9.0 mg.Promoting weight loss In some embodiments, the invention provides a method of promoting weight loss in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable20 salt thereof to the subject once weekly at a dose of 2.4 mg or more.In some embodiments, the invention provides a method of promoting weight loss in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg.25 The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein. In some embodiments, the invention provides a method of promoting weight loss in a30 subject, the method comprising administering petrelintide or a pharmaceutically acceptablesalt thereof to the subject once weekly at a dose of 4.8 mg.In some embodiments, the invention provides a method of promoting weight loss in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable35 salt thereof to the subject once weekly at a dose of 5.0 mg.45 208 In some embodiments, the invention provides a method of promoting weight loss in asubject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg.5 In some embodiments, the invention provides a method of promoting weight loss in asubject, the method comprising administering petrelintide or a pharmaceutically acceptablesalt thereof to the subject once weekly at a dose of 7.0 mg.In some embodiments, the invention provides a method of promoting weight loss in a10 subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg.Reduction of body weight may be expressed as a percentage relative to the start of treatment with petrelintide or within a particular period. Thus, in some embodiments, body 15 weight of the subject is decreased by 2% or more relative to start of treatment with petrelintide. In some embodiments, body weight of the subject is decreased by 2.5% or more, 3% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more, 5.5% or more, 6% or more, 6.5% or more, 7% or more, 7.5% or more, 8% or more, 8.5% or more, 9% or more, 9.5% or more, or 10% or more, such as up to 20%, relative to start of treatment with20 petrelintide. In some embodiments, the body weight of the subject is decreased by about 2% or more,about 2.5% or more, about 3% or more, about 3.5% or more, about 4% or more, about 4.5% or more, about 5% or more, about 5.5% or more, about 6% or more, about 6.5% or more, 25 about 7% or more, about 7.5% or more, about 8% or more, about 8.5% or more, about 9% or more, about 9.5% or more, or about 10% or more relative to their body weight at the start of treatment with petrelintide. In some embodiments, body weight of the subject is decreased by 2% or more over a 16- 30 week period. In some embodiments, body weight of the subject is decreased by 2.5% or more, 3% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more, 5.5% or more, 6% or more, 6.5% or more, 7% or more, 7.5% or more, 8% or more, 8.5% or more, 9% or more, 9.5% or more, or 10% or more over a 16-week period, or after a 16 week period. 35 In some embodiments, body weight of the subject is decreased by about 2.5% or more, about 3% or more, about 3.5% or more, about 4% or more, about 4.5% or more, about 5% or more, about 5.5% or more, about 6% or more, about 6.5% or more, about 7% or more, 46 208 about 7.5% or more, about 8% or more, about 8.5% or more, about 9% or more, about 9.5%or more, or about 10% or more over a 16-week period, or after a 16 week period. The method of the invention of reducing body weight, reducing excess body weight, 5 inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject may alternatively beexpressed as a method of weight management. Thus, the invention provides a method of weight management in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or10 more. The invention provides a method of weight management in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of more than 2.4 mg. In some embodiments, the weight management is chronic weight management.15 Methods of reducing food intake, reducing appetite and increasing satietyIn some embodiments, the invention provides a method of reducing food intake, reducing appetite or increasing satiety in a subject, the method comprising administering petrelintideor a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mgor more. In some embodiments, the invention provides a method of reducing food intake,20 reducing appetite or increasing satiety in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable saltthereof may be any dose described herein.25 In some embodiments, the invention provides a method of reducing food intake in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more.The invention provides a method of reducing food intake in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once30 weekly at a dose of more than 2.4 mg.The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein. The invention provides a method of reducing food intake in a subject, the method comprising35 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg.47 208 The invention provides a method of reducing food intake in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 5.0 mg.5 The invention provides a method of reducing food intake in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg.The invention provides a method of reducing food intake in a subject, the method comprising10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 7.0 mg. The invention provides a method of reducing food intake in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once15 weekly at a dose of 9.0 mg.In some embodiments, the invention provides a method of reducing appetite in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. In some embodiments, the invention20 provides a method of reducing appetite in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at adose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable saltthereof may be any dose described herein.25 In some embodiments, the invention provides a method of increasing satiety in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more. In some embodiments, the inventionprovides a method of increasing satiety in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a30 dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable saltthereof may be any dose described herein.35 means that the subject more readily reaches a state of satiation (i.e., the subject needs to eat less food to reach the point 48 208 the desire to eat food, whereas increasing satiety means the subject will still desire to eat food generally, but will feel satiated sooner and thus eat less food. An effect of petrelintide on a subject undergoing treatment is to induce satiety earlier (i.e., early satiety). 5In some embodiments, the invention provides a method of reducing appetite in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.In some embodiments, the invention provides a method of reducing appetite in a subject, the10 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg.In some embodiments, the invention provides a method of reducing appetite in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof15 to the subject once weekly at a dose of 6.0 mg.In some embodiments, the invention provides a method of reducing appetite in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereofto the subject once weekly at a dose of 7.0 mg.20 In some embodiments, the invention provides a method of reducing appetite in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg.25 In some embodiments, the invention provides a method of increasing satiety in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.In some embodiments, the invention provides a method of increasing satiety in a subject, the30 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg.In some embodiments, the invention provides a method of increasing satiety in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof35 to the subject once weekly at a dose of 6.0 mg.49 208 In some embodiments, the invention provides a method of increasing satiety in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg.5 In some embodiments, the invention provides a method of increasing satiety in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg.Subject 10 and refer to either a human or a non-human animal. These terms include mammals such as humans, non-human primates (e.g., great apes, Old World monkeys and New Worldmonkeys), livestock animals (e.g., bovines and porcines), companion animals (e.g., caninesand felines) and rodents (e.g., mice and rats).15 In some embodiments, the subject is human. In some embodiments, the subject is a human female. In some embodiments of the methods and medical uses of the invention, the subject is 20 overweight, obese or morbidly obese. In some embodiments, the subject is overweight. In some embodiments, the subject is overweight and has at least one weight-related comorbid condition. In some embodiments, the subject is obese. 25 In some embodiments, the subject is morbidly obese. In some embodiments, the subject has a BMI of 25.0 kg / m2to 29.9 kg / m2corresponding to overweight, or a BMI of 30.0 kg / m2to 39.9 kg / m2corresponding to obese, or a BMI of 40.0 or higher corresponding to morbidly obese. 30 In some embodiments, the subject has a BMI of 25.0 kg / m2 or higher corresponding tooverweight, obese or morbidly obese. In some embodiments, the subject has a BMI of 30.0 kg / m2 or higher corresponding to35 obese or morbidly obese. 50 208 In some embodiments, the subject has a BMI of 25.0 kg / m2 to 29.9 kg / m2 corresponding tooverweight. In some embodiments, the subject has a BMI of 30.0 kg / m2to 39.9 kg / m2corresponding to obese. 5 In some embodiments, the subject has a BMI of 40.0 kg / m2or higher corresponding to morbidly obese. The BMI of the subject may decrease over the course of their treatment with petrelintide, as 10 e BMI of the subject before the subject begins administering petrelintide). In some embodiments, the subject has an initial BMI of 25.0 kg / m2 to 29.9 kg / m2corresponding to overweight.15 In some embodiments, the subject has an initial BMI of 30.0 kg / m2 to 39.9 kg / m2corresponding to obese. In some embodiments, the subject has an initial BMI of 40.0 kg / m2 or higher correspondingto morbidly obese. 20 In some embodiments of the methods and medical uses of the invention, the subject has an initial BMI of 30 kg / m2or greater (obesity). In some embodiments of the methods and medical uses of the invention, the subject has an initial BMI of 27 kg / m2or greater (overweight) in the presence of at least one weight-related 25 comorbid condition In some embodiments, the subject is an adult. In some embodiments, the subject is a paediatric patient aged 12 years or older. In some embodiments, the subject is an adult with obesity. 30 In some embodiments, the subject is an adult or a paediatric patient aged 12 years or older with obesity. In some embodiments, the subject is an adult with overweight in the presence of at least one weight-related comorbid condition.35 As described herein, a -the 51 208 diseases and conditions described herein as - Patient sub-groups 5As described herein, petrelintide exhibits a favourable ratio of exposure to adverse events. Itis possible to increase the exposure of petrelintide (by increasing the dose of petrelintide) without decreasing the safety profile in terms of adverse events compared to lower exposures of petrelintide. In other words, though exposure to petrelintide increases, adverse events (such as nausea and vomiting) do not increase further. 10 The present invention may therefore be particularly useful in respect of treatment of subjects who are especially sensitive to gastrointestinal adverse events (i.e., gastrointestinalconditions or disorders), such as nausea, vomiting, diarrhea or constipation. In other words, the invention may be particularly useful in treating a sub-group of patients who are sensitive15 to gastrointestinal adverse events. In some embodiments, the subject is sensitive to a gastrointestinal adverse event. In someembodiments, the gastrointestinal adverse event is nausea, vomiting, diarrhea orconstipation. In some embodiments, the gastrointestinal adverse event is diarrhea. The term20 adverse event experience a gastrointestinal adverse event than other subjects. As described herein, gastrointestinal adverse events are well-known for obesity drugs suchas semaglutide and cagrilintide. Some subjects may be unable to take such obesity drugs25 due to the gastrointestinal adverse events caused by the obesity drug. However, given thefavourable ratio of exposure to adverse events exhibited by petrelintide, as shown in the present application, such subjects may be able to take petrelintide instead. In other words, the invention may be particularly useful in treating a sub-group of patients who cannot take other obesity drugs. 30 Thus, in some embodiments, the subject is unable to take another obesity drug due to gastrointestinal adverse events. In some embodiments, the subject is unable to take another stinal adverse event. In someembodiments, the gastrointestinal adverse event is nausea, vomiting, diarrhea or 35 constipation. In some embodiments, the gastrointestinal adverse event is diarrhea. 52 208 as used herein means anymedicament used for reducing body weight, other than petrelintide. In some embodiments, the other obesity drug is cagrilintide. In some embodiments, the 5subject is other obesity drug is an incretin peptide hormone. In some embodiments, theincretin peptide hormone is a GLP-1 analogue. In some embodiments, the incretin peptide hormone is semaglutide. In some embodiments, the incretin peptide hormone is tirzepatide. The subject may have previously taken another obesity drug (i.e., an obesity drug other than10 petrelintide) and had to cease treatment with the other obesity drug due to gastrointestinaladverse events. In other words, the invention may be particularly useful in treating a sub- group of patients who have ceased treatment with another obesity drug due togastrointestinal adverse events caused by the other obesity drug. 15 Thus, in some embodiments, the subject has ceased treatment with another obesity drug. In some embodiments, the subject has ceased treatment with another obesity drug due to a gastrointestinal adverse event. another obesity drug 20 longer receiving (i.e., the subject has stopped taking) the other obesity drug. In other words, the other obesity drug has ceased to be administered to the subject. There may be no intentthat the subject will take future doses of the other obesity drug. The subject may have ceased treatment with the balanced GLP-1R agonist for any reason,25 such as due to advice from their physician. The subject may have ceased treatment with the other obesity drug at any previous point intheir life, such as in the recent past or in the distant past. In some embodiments, the subjectceased treatment with the other obesity drug about one week or more ago, about one month30 or more ago, about six months or more ago, or about one year or more ago. The subject may have previously ceased treatment with the other obesity drug and thenrestarted treatment with the other obesity, only to then again cease treatment with the obesity drug. This may have occurred any number of times in the past life of the subject. 35 53 208 Thus, the present invention may be useful as a second-line therapy wherein previous treatment with another obesity drug has been ceased due to non-responsiveness orunwanted side-effects. 5 In some embodiments, the other obesity drug is cagrilintide. In some embodiments, the subject is other obesity drug is an incretin peptide hormone. In some embodiments, the incretin peptide hormone is a GLP-1 analogue. In some embodiments, the incretin peptide hormone is semaglutide. In some embodiments, the incretin peptide hormone is tirzepatide. 10 Treatment with petrelintide may be useful for a subject who cannot take other obesity drugs due to contraindications for those obesity drugs. In other words, the invention may be particularly useful in treating a sub-group of patients who suffer from a condition which is n in a subject that indicates that a given drug should not be administered to the subject. In 15 other words, if the subject has the disease (i.e., the contraindication) they should not be given the drug. The contraindication(s) for a drug are presented on th embodiments, the subject suffers from a disease which is contraindicated for another obesity drug.20Non-therapeutic methods Petrelintide may be used for non-therapeutic purposes. In this respect, it may be desirable for a subject to reduce food intake to lose weight (or inhibit weight gain) despite the subjectnot being obese or morbidly obese, such as for cosmetic reasons. Administration of petrelintide may achieve these desired effects (reduced body weight, reduced food intake,25 weight loss and / or inhibited weight gain). In such embodiments, administration of petrelintide to the subject would not be therapeutic as no disease or disorder would be being treated by petrelintide. Thus, in some embodiments, the method of the invention is a non-therapeutic method. Thus,30 in some embodiments, the method of the invention is a cosmetic method.Thus, the invention further provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term,reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a35 subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg or more.54 208 The invention further provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof 5 to the subject once weekly at a dose of more than 2.4 mg. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein.10 In some embodiments, the invention provides a non-therapeutic method of reducing bodyweight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.15 In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically20 acceptable salt thereof to the subject once weekly at a dose of 5.0 mg.In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight25 loss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg.In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction30 long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg.In some embodiments, the invention provides a non-therapeutic method of reducing body35 weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight55 208 loss, in a subject, the method comprising administering petrelintide or a pharmaceuticallyacceptable salt thereof to the subject once weekly at a dose of 9.0 mg.In some embodiments, the invention provides a non-therapeutic method of reducing body 5 weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg or more.10 In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg or more.15 In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically20 acceptable salt thereof to the subject once weekly at a dose of 6.0 mg or more.In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight25 loss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg or more.In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction30 long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg or more.The non-therapeutic nature of certain methods of the invention is particularly pertinent when 35 the subject is of healthy weight (i.e. a subject that is not overweight, obese or morbidly obese). Administration of petrelintide to a subject of healthy weight, for which there are notherapeutic reasons to reduce body fat, is a cosmetic (non-therapeutic) method. 56 208 Healthy weight is defined in the medical field by body mass index (BMI). In some embodiments of the non-therapeutic method of the invention, the subject has a BMIof 18.5 kg / m2to 24.9 kg / m2corresponding to healthy weight. 5In some embodiments of the non-therapeutic method of the invention, the subject has a BMIof 25.0 kg / m2to 29.9 kg / m2corresponding to overweight. Thus, in some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight10 reduction long term, reducing food intake, reducing appetite, increasing satiety or promotingweight loss in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 2.4 mg ormore, wherein the subject is a healthy weight or overweight. 15 In some embodiments, the invention provides a non-therapeutic method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss in a subject, the method comprising administering petrelintide or a pharmaceuticallyacceptable salt thereof to the subject once weekly at a dose of more than 2.4 mg, wherein20 the subject is a healthy weight or overweight. The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein.25 In some embodiments of the non-therapeutic method of the invention, the subject is notobese or morbidly obese. Considerations regarding petrelintide or a pharmaceutically acceptable salt thereof asoutlined herein apply equally when petrelintide or a pharmaceutically acceptable salt thereof30 is used for therapeutic and non-therapeutic purposes. Dose The dose of petrelintide or a pharmaceutically acceptable salt thereof may be any dosedescribed herein. 35 The dose of the non-incretin peptide hormone or a pharmaceutically acceptable salt thereof may be any dose described herein. 57 208 of petrelintide or non-incretin peptide hormoneadministered to the subject at each administration event.means an amount of petrelintide or non-incretin peptide hormone.particular mass of petrelintide or non-incretin peptide hormone, which is typically measured5 in milligrams (mg), e.g., 4.8 mg, 5.0 mg, 6.0 mg, 7.0 mg or 9.0 mg. The dose of petrelintide may be independently selected at each administration event. s10 administered to a subject. The exact dosage employed will depend, inter alia, on: the natureand severity of the disease or disorder to be treated, on the sex, age, body weight and general condition of the subject to be treated, on possible other, concomitant, disease or disorder that is undergoing or is to undergo treatment, as well as on other factors that will be known to a medical practitioner of skill in the art. 15 All doses described herein are administered to the subject once weekly, in accordance with the invention. 20 administered once weekly. According to the invention, petrelintide is administered to the subject at a dose of 2.4 mg or more. According to the invention, petrelintide is administered to the subject at a dose of 25 about 2.4 mg or more. expressions are used interchangeably herein. Thus, in other words, petrelintide is administered to the subject at a dose of 2.4 mg or higher. Alternatively expressed, petrelintide is administered to the subject at a dose of at least 2.4 mg. mg or mg or higher amount of30 petrelintide described herein) have the same meaning.petrelintide is administered to the subject at a dose of is any dose described herein) means that X milligrams of petrelintide (i.e., the specified amount of petrelintide, in milligrams) is administered to the subject, by any means, in a35 single administration event. 58 208 For example, the expression administering petrelintide or a pharmaceutically acceptablesalt thereof to the subject about once weekly at a dose of about 2.4 mg or moreprocess wherein a subject (such as a human) is administered (such as by subcutaneous injection) an amount of petrelintide which is about 2.4 milligrams or more (such as about 2.45 milligrams, or about 4.8 milligrams, or about 9.0 milligrams) about once per week (i.e., about once every 7 days), as described herein. That is, an amount of at least about 2.4 milligrams of petrelintide is introduced into the s event) each weekfor the entirety of the administration period (i.e., for the entire period the subject is receiving petrelintide). 10 Petrelintide may be administered by any appropriate means known in the art, such as by subcutaneous injection. Accordingly, the form in which petrelintide is delivered may be any appropriate form known in the art. For example, administration by subcutaneous injection requires petrelintide to be dissolved in solution (i.e., in a liquid pharmaceutical formulation). 15 However, regardless of the form in which petrelintide is administered, the amount of petrelintide in milligrams (mg) which is administered at each administration event is a precisely defined amount. For example, when a solution comprising petrelintide isadministered to a subject, the amount of petrelintide in milligrams which is administered to the subject is known from the concentration of petrelintide in the solution (which is 20 determined when the solution is manufactured) and the amount in millilitres (mL) of the solution which is administered to the subject. The amount of petrelintide which is administered to a subject at any given administration event is therefore determined by the amount of petrelintide in the medicament being 25 administered (which is determined by manufacture of the medicament) and the amount of the medicament that is administered. The actual amount of petrelintide administered (i.e., the dose of petrelintide) is not defined by other factors, such as e.g., the weight of the subject. 30 Accordingly, the dose of approved peptide hormone weight loss drugs available on the market (semaglutide and tirzepatide) is a fixed dose, which does not vary according to the weight of the subject. Whilst a physician may determine the dose of drug to give according to Afixed dose for weight management drugs, such as petrelintide, is possible35 because such products have a broad therapeutic index i.e., a large difference between toxic and therapeutic doses. From a patient safety point of view, having a fixed dose can reduce59 208 medication errors (and consequently adverse events). One or more fixed doses can beoffered, independent of weight. To put it another way, the present invention may be considered to relate to a dosage regime 5 for a subject taking petrelintide. According to the present invention, the subject takes petrelintide once weekly, at a dose of more than 2.4 mg. The subject may take petrelintide once weekly at a dose of 4.8 mg, 5.0 mg, 6.0 mg, 7.0 mg or 9.0 mg. The petrelintide dosageregime may have been prescribed by a physician, who determines the precise amount (i.e.,dose) of petrelintide the subject should be administered at each administration event. An10 amount of petrelintide of more than 2.4 mg is according to the present invention. Minimum doses 4.8 mg or more 15 In some embodiments, the dose of petrelintide is 4.8 mg or more. Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or adisease linked to overweight, obesity or diabetes, or of reducing body weight, reducing20 excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereofto the subject once weekly at a dose of 4.8 mg or more.25 The invention provides a method of treating overweight, overweight in the presence of atleast one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method30 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject about once weekly at a dose of about 4.8 mg or more.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related35 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a60 208 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg ormore. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use5 in a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg or more.10 The invention also provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprisingadministering petrelintide to the subject once weekly at a dose of 4.8 mg or more.15 The invention also provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject aboutonce weekly at a dose of about 4.8 mg or more.20 The invention also provides a method of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the25 subject once weekly at a dose of 4.8 mg or more.The invention also provides a method of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method30 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject about once weekly at a dose of about 4.8 mg or more.5.0 mg or more In some embodiments, the dose of petrelintide is 5.0 mg or more. 35 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a 61 208 disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof 5 to the subject once weekly at a dose of 5.0 mg or more. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,10 obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg ormore. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use15 in a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 5.0 mg or more.20 6.0 mg or more In some embodiments, the dose of petrelintide is 6.0 mg or more. Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a25 disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg or more. 30 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a35 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg ormore. 62 208 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once5 weekly at a dose of 6.0 mg or more.7.0 mg or more In some embodiments, the dose of petrelintide is 7.0 mg or more.10 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or adisease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the15 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg or more. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related20 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg ormore.25 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 7.0 mg or more.30 9.0 mg or more In some embodiments, the dose of petrelintide is 9.0 mg or more. Thus, the invention provides a method of treating overweight, overweight in the presence of35 at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing 63 208 food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg or more. 5The invention also provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the10 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of about 9.0 mg or more.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related15 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg ormore.20 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 9.0 mg or more.25 The invention also provides a method of treating overweight in the presence of at least oneweight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a30 dose of 9.0 mg or more. The invention also provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising35 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject aboutonce weekly at a dose of about 9.0 mg or more. 64 208 The invention also provides a method of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to the5 subject once weekly at a dose of 9.0 mg or more.The invention also provides a method of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method10 comprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject about once weekly at a dose of about 9.0 mg or more.Other minimum doses In some embodiments of the invention, the dose of petrelintide or a pharmaceutically15 acceptable salt thereof is 3.0 mg or more, 3.6 mg or more, 4.0 mg or more, 4.8 mg or more,5.0 mg or more, 6.0 mg or more, 7.0 mg or more, 7.5 mg or more, 8.0 mg or more, or 9.0 mg or more. In some embodiments, the dose is about 2.5 mg or more, about 2.6 mg or more, about 2.720 mg or more, about 2.8 mg or more, about 2.9 mg or more, about 3.0 mg or more, about 3.1 mg or more, about 3.2 mg or more, about 3.3 mg or more, about 3.4 mg or more, about 3.5mg or more, about 3.6 mg or more, about 3.7 mg or more, about 3.8 mg or more, about 3.9mg or more, about 4.0 mg or more, about 4.1 mg or more, about 4.2 mg or more, about 4.3mg or more, about 4.4 mg or more, about 4.5 mg or more, about 4.6 mg or more, about 4.725 mg or more, about 4.8 mg or more, about 4.9 mg or more, about 5.0 mg or more, about 5.5mg or more, about 6.0 mg or more, about 6.5 mg or more, about 7.0 mg or more, about 7.5 mg or more, about 8.0 mg or more, about 8.5 mg or more, or about 9.0 mg or more. In some embodiments, the dose is more than 2.4 mg. In other words, in some embodiments, 30 the dose is higher than 2.4 mg. Alternatively expressed, the dose is not less than or equal to 2.4 mg. In some embodiments, the dose is more than 3.0 mg, more than 3.6 mg, more than 4.0 mg, more than 4.8 mg, more than 5.0 mg, more than 6.0 mg, more than 7.0 mg, more than 7.5 mg, or more than 8.0 mg or more than 9.0 mg.35 In some embodiments, the dose is more than about 2.4 mg, more than about 2.5 mg, morethan about 2.6 mg, more than about 2.7 mg, more than about 2.8 mg, more than about 2.9mg, more than about 3.0 mg, more than about 3.1 mg, more than about 3.2 mg, more than65 208 about 3.3 mg, more than about 3.4 mg, more than about 3.5 mg, more than about 3.6 mg,more than about 3.7 mg, more than about 3.8 mg, more than about 3.9 mg, more than about4.0 mg, more than about 4.1 mg, more than about 4.2 mg, more than about 4.3 mg, morethan about 4.4 mg, more than about 4.5 mg, more than about 4.6 mg, more than about 4.75 mg, more than about 4.8 mg, more than about 4.9 mg, more than about 5.0 mg, more thanabout 5.5 mg, more than about 6.0 mg, more than about 6.5 mg, more than about 7.0 mg,more than about 7.5 mg, more than 8.0 mg, or more than about 8.5 mg.Maximum doses 10 In some embodiments, the dose is at most 10.0 mg. In some embodiments, the dose is at most 9.5 mg. In some embodiments, the dose is at most 9.0 mg. In some embodiments, the dose is at most about 10.0 mg. In some embodiments, the dose is at most about 9.5 mg. In some embodiments, the dose is at most about 9.0 mg. 15 Dose ranges 4.8 mg to 9.0 mg In some embodiments, the dose of petrelintide is from 4.8 mg to 9.0 mg.20 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing25 food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 4.8 mg to 9.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use30 in a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 4.8 mgto 9.0 mg. 35 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related66 208 comorbid condition, obesity or morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 4.8 mg to 9.0 mg.5 5.0 mg to 9.0 mg In some embodiments, the dose of petrelintide is from 5.0 mg to 9.0 mg.Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a10 disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereofto the subject once weekly at a dose of from 5.0 mg to 9.0 mg.15 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a20 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 5.0 mgto 9.0 mg. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related25 comorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 5.0 mg to 9.0 mg.6.0 mg to 9.0 mg30 In some embodiments, the dose of petrelintide is from 6.0 mg to 9.0 mg.Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or adisease linked to overweight, obesity or diabetes, or of reducing body weight, reducing35 excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the67 208 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 6.0 mg to 9.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use5 in a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 6.0 mgto 9.0 mg. 10 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once15 weekly at a dose of from 6.0 mg to 9.0 mg.7.0 mg to 9.0 mg In some embodiments, the dose of petrelintide is from 7.0 mg to 9.0 mg.20 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the25 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 7.0 mg to 9.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related30 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 7.0 mgto 9.0 mg.35 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising 68 208 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 7.0 mg to 9.0 mg.4.8 mg to 10.0 mg 5 In some embodiments, the dose of petrelintide is from 4.8 mg to 10.0 mg. Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing10 excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 4.8 mg to 10.0 mg.15 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 4.8 mg20 to 10.0 mg. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising25 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 4.8 mg to 10.0 mg.5.0 mg to 10.0 mg In some embodiments, the dose of petrelintide is from 5.0 mg to 10.0 mg.30 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing35 food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 5.0 mg to 10.0 mg.69 208 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, 5obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 5.0 mgto 10.0 mg. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use10 in a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 5.0 mg to 10.0 mg.15 6.0 mg to 10.0 mg In some embodiments, the dose of petrelintide is from 6.0 mg to 10.0 mg.Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a20 disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 6.0 mg to 10.0 mg.25 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a30 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 6.0 mgto 10.0 mg. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related35 comorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject aboutonce weekly at a dose of from 6.0 mg to 10.0 mg.70 208 7.0 mg to 10.0 mg In some embodiments, the dose of petrelintide is from 7.0 mg to 10.0 mg.5 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the10 method comprising administering petrelintide or a pharmaceutically acceptable salt thereofto the subject once weekly at a dose of from 7.0 mg to 10.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related15 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of from 7.0 mgto 10.0 mg.20 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of from 7.0 mg to 10.0 mg.25 Other dose ranges In some embodiments, the dose is from 2.4 mg to 10.0 mg. In some embodiments, the dose is from 3.6 mg to 10.0 mg, from 4.0 mg to 10.0 mg, from 4.8 mg to 9.0 mg, from 4.8 mg to 10.0 mg, from 6.0 mg to 10.0 mg, from 7.5 mg to 10.0 mg, or from 9.0 mg to 10.0 mg. 30 In some embodiments, the dose is from about 2.4 mg to about 10.0 mg, from about 2.5 mgto about 10.0 mg, from about 2.6 mg to about 10.0 mg, from about 2.7 mg to about 10.0 mg,from about 2.8 mg to about 10.0 mg, from about 2.8 mg to about 10.0 mg, from about 2.9 mgto about 10.0 mg, from about 3.0 mg to about 10.0 mg, from about 3.1 mg to about 10.0 mg,35 from about 3.2 mg to about 10.0 mg, from about 3.3 mg to about 10.0 mg, from about 3.4 mgto about 10.0 mg, from about 3.5 mg to about 10.0 mg, from about 3.6 mg to about 10.0 mg,from about 3.7 mg to about 10.0 mg, from about 3.8 mg to about 10.0 mg, from about 3.9 mg71 208 to about 10.0 mg, from about 4.0 mg to about 10.0 mg, from about 4.1 mg to about 10.0 mg,from about 4.2 mg to about 10.0 mg, from about 4.3 mg to about 10.0 mg, from about 4.4 mgto about 10.0 mg, from about 4.5 mg to about 10.0 mg, from about 4.6 mg to about 10.0 mg,from about 4.7 mg to about 10.0 mg, from about 4.8 mg to about 10.0 mg, from about 4.9 mg5 to about 10.0 mg, from about 5.0 mg to about 10.0 mg, from about 5.5 mg to about 10.0 mg,from about 6.0 mg to about 10.0 mg, from about 7.0 mg to about 10.0 mg, from about 7.5 mg to about 10.0 mg, from about 8.0 mg to about 10.0 mg, from about 8.5 mg to about 10.0 mg,or from about 9.0 mg to about 10.0 mg. 10 In some embodiments, the dose is from 2.4 mg to 9.0 mg, from 3.6 mg to 9.0 mg, from 4.0 mg to 9.0 mg, from 4.8 mg to 9.0 mg, from 6.0 mg to 9.0 mg, or from 7.5 mg to 9.0 mg. In some embodiments, the dose is from 6.1 mg to 9.0 mg, from 6.5 mg to 9.0 mg, from 7.0 mg to 9.0 mg, from 8.0 mg to 9.0 mg, or from 8.5 mg to 9.0 mg.15 In some embodiments, the dose is from about 2.4 mg to about 9.0 mg, from about 2.5 mg toabout 9.0 mg, from about 2.6 mg to about 9.0 mg, from about 2.7 mg to about 9.0 mg, fromabout 2.8 mg to about 9.0 mg, from about 2.8 mg to about 9.0 mg, from about 2.9 mg toabout 9.0 mg, from about 3.0 mg to about 9.0 mg, from about 3.1 mg to about 9.0 mg, fromabout 3.2 mg to about 9.0 mg, from about 3.3 mg to about 9.0 mg, from about 3.4 mg to20 about 9.0 mg, from about 3.5 mg to about 9.0 mg, from about 3.6 mg to about 9.0 mg, fromabout 3.7 mg to about 9.0 mg, from about 3.8 mg to about 9.0 mg, from about 3.9 mg toabout 9.0 mg, from about 4.0 mg to about 9.0 mg, from about 4.1 mg to about 9.0 mg, fromabout 4.2 mg to about 9.0 mg, from about 4.3 mg to about 9.0 mg, from about 4.4 mg toabout 9.0 mg, from about 4.5 mg to about 9.0 mg, from about 4.6 mg to about 9.0 mg, from25 about 4.7 mg to about 9.0 mg, from about 4.8 mg to about 9.0 mg, from about 4.9 mg toabout 9.0 mg, from about 5.0 mg to about 9.0 mg, from about 5.5 mg to about 9.0 mg, fromabout 6.0 mg to about 9.0 mg, from about 6.1 mg to about 9.0 mg, from about 6.5 mg to about 9.0 mg, from about 7.0 mg to about 9.0 mg, from about 7.5 mg to about 9.0 mg, from about 8.0 mg to about 9.0 mg, or from about 8.5 mg to about 9.0 mg. 30 In some embodiments, the dose is more than 2.4 mg up to 10.0 mg. In other words, in some embodiments, the dose is higher than 2.4 mg, up to at most 10.0 mg. In some embodiments, the dose is more than 3.6 mg up to 10.0 mg, more than 4.0 mg up to 10.0 mg, more than 4.8 mg up to 10.0 mg, more than 6.0 mg up to 10.0 mg, or more than 7.5 mg up to 10.0 mg. 35 In some embodiments, the dose is more than about 2.4 mg up to about 10.0 mg, more thanabout 2.5 mg up to about 10.0 mg, more than about 2.6 mg up to about 10.0 mg, more than72 208 about 2.7 mg up to about 10.0 mg, more than about 2.8 mg up to about 10.0 mg, more thanabout 2.9 mg up to about 10.0 mg, more than about 3.0 mg up to about 10.0 mg, more thanabout 3.1 mg up to about 10.0 mg, more than about 3.2 mg up to about 10.0 mg, more thanabout 3.3 mg up to about 10.0 mg, more than about 3.4 mg up to about 10.0 mg, more than5 about 3.5 mg up to about 10.0 mg, more than about 3.6 mg up to about 10.0 mg, more thanabout 3.7 mg up to about 10.0 mg, more than about 3.8 mg up to about 10.0 mg, more thanabout 3.9 mg up to about 10.0 mg, more than about 4.0 mg up to about 10.0 mg, more thanabout 4.1 mg up to about 10.0 mg, more than about 4.2 mg up to about 10.0 mg, more thanabout 4.3 mg up to about 10.0 mg, more than about 4.4 mg up to about 10.0 mg, more than10 about 4.5 mg up to about 10.0 mg, more than about 4.7 mg up to about 10.0 mg, more thanabout 4.8 mg up to about 10.0 mg, more than about 4.9 mg up to about 10.0 mg, more thanabout 5.0 mg up to about 10.0 mg, more than about 5.5 mg up to about 10.0 mg, more thanabout 6.0 mg up to about 10.0 mg, more than about 6.5 mg up to about 10.0 mg, more thanabout 7.0 mg up to about 10.0 mg, more than about 7.5 mg up to about 10.0 mg, more than15 about 8.0 mg up to about 10.0 mg, more than about 8.5 mg up to about 10.0 mg, or morethan about 9.0 mg up to about 10.0 mg.In some embodiments the dose is more than 2.4 mg up to 9.0 mg. In some embodiments, the dose is more than 3.6 mg up to 9.0 mg, more than 4.0 mg up to 9.0 mg, or more than 4.8 20 mg up to 9.0 mg. In some embodiments, the dose is more than 6.0 mg up to 9.0 mg. In other words, in some embodiments, the dose is higher than 6.0 mg, up to at most 9.0 mg. In some embodiments, the dose is more than 7.5 mg up to 9.0 mg. In some embodiments, the dose is more than about 2.4 mg up to about 9.0 mg, more than25 about 2.5 mg up to about 9.0 mg, more than about 2.6 mg up to about 9.0 mg, more thanabout 2.7 mg up to about 9.0 mg, more than about 2.8 mg up to about 9.0 mg, more thanabout 2.9 mg up to about 9.0 mg, more than about 3.0 mg up to about 9.0 mg, more thanabout 3.1 mg up to about 9.0 mg, more than about 3.2 mg up to about 9.0 mg, more thanabout 3.3 mg up to about 9.0 mg, more than about 3.5 mg up to about 9.0 mg, more than30 about 3.6 mg up to about 9.0 mg, more than about 3.7 mg up to about 9.0 mg, more thanabout 3.8 mg up to about 9.0 mg, more than about 3.9 mg up to about 9.0 mg, more thanabout 4.0 mg up to about 9.0 mg, more than about 4.1 mg up to about 9.0 mg, more thanabout 4.2 mg up to about 9.0 mg, more than about 4.3 mg up to about 9.0 mg, more thanabout 4.4 mg up to about 9.0 mg, more than about 4.5 mg up to about 9.0 mg, more than35 about 4.6 mg up to about 9.0 mg, more than about 4.7 mg up to about 9.0 mg, more thanabout 4.8 mg up to about 9.0 mg, more than about 4.9 mg up to about 9.0 mg, more thanabout 5.0 mg up to about 9.0 mg, more than about 5.5 mg up to about 9.0 mg, more than73 208 about 6.0 mg up to about 9.0 mg, more than about 6.5 mg up to about 9.0 mg, more thanabout 7.0 mg up to about 9.0 mg, more than about 7.5 mg up to about 9.0 mg, or more thanabout 8.0 mg up to about 9.0 mg.5 Specific doses4.8 mg In some embodiments, the dose of petrelintide is 4.8 mg.10 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the15 method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg. The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related20 comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 4.8 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for use25 in a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg.30 The invention also provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 4.8 mg.35 The invention also provides a method of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, 74 208 reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 4.8 mg.5 5.0 mg In some embodiments, the dose of petrelintide is 5.0 mg. Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a10 disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg. 15 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a20 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 5.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising25 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 5.0 mg.6.0 mg In some embodiments, the dose of petrelintide is 6.0 mg. 30 Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing35 food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg. 75 208 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, 5obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 6.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related10 comorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 6.0 mg.7.0 mg 15 In some embodiments, the dose of petrelintide is 7.0 mg. Thus, the invention provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing20 excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg.25 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject once weekly at a dose of 7.0 mg.30 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject once35 weekly at a dose of 7.0 mg.76 208 9.0 mg In some embodiments, the dose of petrelintide is 9.0 mg. Thus, the invention provides a method of treating overweight, overweight in the presence of5 at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide to the subject once weekly at a dose of 9.0 mg. 10 The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a15 pharmaceutically acceptable salt thereof to the subject once weekly at a dose of 9.0 mg.The invention also provides petrelintide or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity or morbid obesity in a subject, the method comprising20 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 9.0 mg.The invention also provides a method of treating overweight, overweight in the presence ofat least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a25 disease linked to overweight, obesity or diabetes in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject onceweekly at a dose of 9.0 mg.The invention also provides a method of reducing body weight, reducing excess body30 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof to thesubject once weekly at a dose of 9.0 mg.35 Other doses In some embodiments, the dose is 2.4 mg. In some embodiments, the dose is 2.5 mg. Insome embodiments, the dose is 3.6 mg. In some embodiments, the dose is 4.0 mg. In some 77 208 embodiments, the dose is 4.8 mg. In some embodiments, the dose is 5.0 mg. In someembodiments, the dose is 7.0 mg. In some embodiments, the dose is 7.5 mg. In someembodiments, the dose is 9.0 mg. 5In some embodiments, the dose is about 2.4 mg, about 2.5 mg, about 3.0 mg, about 3.6 mg,about 4.0 mg, about 4.8 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 7.5 mg, about 8.0 mg, about 8.5 mg, about 9.0 mg, about 9.5 mg, or about10.0 mg.10 In some embodiments, the dose is 2.4 mg, 3.6 mg, 4.0 mg, 4.8 mg, 6.0 mg, 7.5 mg or 9.0mg. In some embodiments, the dose is about 2.4 mg, about 3.6 mg, about 4.0 mg, about 4.8mg, about 6.0 mg, about 7.5 mg or about 9.0 mg. In some embodiments, the dose is 2.5 mg, 5.0 mg, 7.0 mg or 9.0 mg. In some embodiments,15 the dose is about 2.5 mg, about 5.0 mg, about 7.0 mg or about 9.0 mg.In some embodiments, the dose is about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, about 3.2 mg, about 3.3 mg, about 3.4 mg, about 3.5 mg, about 3.6 mg, about 3.7 mg, about 3.8 mg, about 3.9 mg, about 4.0 20 mg, about 4.1 mg, about 4.2 mg, about 4.3 mg, about 4.4 mg, about 4.5 mg, about 4.6 mg, about 4.7 mg, about 4.8 mg, about 4.9 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 7.5 mg, about 8.0 mg, about 8.5 mg, or about 9.0 mg.In some embodiments, the dose of petrelintide is not the same during each administration. In 25 some embodiments, the dose of petrelintide is increased for each successive administration. In some embodiments, the dose of petrelintide is increased for each successive administration until a desired maximum dose is reached. Optionally, the desired maximum dose may be maintained over a given time period (i.e. the dosage plateaus). In some embodiments, the dose of petrelintide is the same during each administration. 30 Once weekly administration According to the present invention, petrelintide is once .In other words, petrelintide is administered to the subject once .Alternatively expressed, the subject receives a single dose of petrelintide once in each week. 35 6.5, 7, 7.5, 8, 8.5 or 9 days, -hour78 208 period. As will be appreciated in the art, the time between doses may be varied to someextent so that each and every dose is not separated by precisely the same time (i.e., not precisely one week). Thus, in some embodiments, petrelintide is administered to the subject about once weekly. 5 In an alternative aspect, petrelintide is Route of administration The administration to a subject of petrelintide described herein may be by any mode of10 administration common or standard in the art. In some embodiments, petrelintide isadministered to the subject by injection, such as by subcutaneous (sc), intramuscular (im) or intravenous (iv) injection. In preferred embodiments, administration is by subcutaneous injection. Preferably, petrelintide is in a form suitable for subcutaneous (s / c or s.c.)administration to a subject. 15 Administration period The term may be used herein to refer to the total period in which petrelintide is administered to the subject. In other words, the administration period is theperiod starting with the first administration event (i.e. the first time petrelintide is administered20 to the subject) and ending with the final administration event (i.e. the final time petrelintide isadministered to the subject). Alternatively expressed, the administration period is the periodin which subject is treated with petrelintide. In some embodiments, petrelintide is administered to the subject for at least one month (i.e.25 the administration period for petrelintide is at least one month). In some embodiments, petrelintide is administered to the subject for at least two months, at least three months, atleast four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, or at least twelve months. 30 In some embodiments, petrelintide is administered to the subject for at least one year (i.e.the administration period for petrelintide is at least one year). In some embodiments petrelintide is administered to the subject for at least two years, at least three years, at least four years, at least five years, at least six years, at least seven years, at least eight years, at35 least nine years, or at least ten years or more.79 208 In some embodiments, administration of petrelintide is chronic. In other words, in some embodiments, the method comprises administering petrelintide as a chronic treatment. Inother words, in some embodiments, the method comprises chronic administration of g treatment to manage a disease or condition 5 which has no cure. Chronic treatment is particularly relevant to weight management (i.e., reducing body weight and then maintaining reduced body weight) as regain of body weight remains possible throughout the life of a subject. In some embodiments, petrelintide is administered to the subject for more than ten years. In 10 some embodiments, petrelintide is administered to the subject indefinitely. In some embodiments, petrelintide is administered to the subject for Gastrointestinal adverse events 15 subjects whilst taking petrelintide. In other words, an adverse event is an unfavourable and unintended medical condition or event. - 20 In some embodiments, the subject experiences fewer or the same number of adverse events compared to when the subject is administered petrelintide once weekly at a dose lower than 2.4 mg. 25 In some embodiments, the subject experiences adverse events of the same or lesser severity compared to when the subject is administered petrelintide once weekly at a doselower than 2.4 mg. As described herein, administration of petrelintide once weekly at higher doses results in 30 greater weight loss whilst gastrointestinal adverse events do not increase in frequency or severity relative to lower (see particularly Tables 10 and 11 in Example 3). 35 administered once weekly. 80 208 Accordingly, in some embodiments, the subject experiences fewer or the same number of gastrointestinal adverse events compared to when the subject is administered petrelintide once weekly at a dose lower than 2.4 mg. 5 In some embodiments, the subject experiences gastrointestinal adverse events of the same or lesser severity compared to when the subject is administered petrelintide once weekly at a dose lower than 2.4 mg. The terms gastrointestinal adverse disorder are used10 interchangeably and refer herein to any unexpected gastrointestinal reaction to petrelintide. In some embodiments, the gastrointestinal adverse event is nausea, abdominal pain,vomiting, fatigue, dizziness diarrhea, constipation, or dyspepsia. In some embodiments, thegastrointestinal adverse event is selected from the group consisting of nausea, abdominalpain, and vomiting. In some embodiments, the gastrointestinal adverse event is diarrhea.15 In some embodiments, the subject experiences fewer or the same number of gastrointestinaladverse events compared to when the subject is administered petrelintide or a pharmaceutically acceptable salt thereof once weekly at a dose lower than 2.4 mg, whereinthe gastrointestinal adverse event is selected from diarrhea and constipation. In some20 embodiments, the subject experiences fewer or the same number of gastrointestinal adverse events compared to when the subject is administered petrelintide or a pharmaceutically acceptable salt thereof once weekly at a dose lower than 2.4 mg, wherein thegastrointestinal adverse event is diarrhea. In some embodiments, the subject experiences fewer or the same number of gastrointestinal adverse events compared to when the subject25 is administered petrelintide or a pharmaceutically acceptable salt thereof once weekly at adose lower than 2.4 mg, wherein the gastrointestinal adverse event is constipation. In some embodiments, the subject experiences gastrointestinal adverse events of the same or lesser severity compared to when the subject is administered petrelintide or a30 pharmaceutically acceptable salt thereof once weekly at a dose lower than 2.4 mg, whereinthe gastrointestinal adverse event is selected from diarrhea and constipation. In someembodiments, the subject experiences gastrointestinal adverse events of the same or lesser severity compared to when the subject is administered petrelintide or a pharmaceuticallyacceptable salt thereof once weekly at a dose lower than 2.4 mg, wherein the35 gastrointestinal adverse event is diarrhea. In some embodiments, the subject experiences gastrointestinal adverse events of the same or lesser severity compared to when the subject 81 208 is administered petrelintide or a pharmaceutically acceptable salt thereof once weekly at adose lower than 2.4 mg, wherein the gastrointestinal adverse event is constipation. In some embodiments, the subject does not experience diarrhea. 5 The invention also provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing10 food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, themethod comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject, wherein the subject does not experience diarrhea. 15 . The term "safety profile" as used herein refers to adverse events of an administered drug or petrelintide and includes gastrointestinal adverse events, such as nausea, abdominal pain and vomiting. In some embodiments the term "increase in safety profile" as used herein 20 refers to an increase in safety events, such as an increase in gastrointestinal adverse events. The severity of gastrointestinal adverse events may be graded as follows: Mild: A type of adverse event that is usually transient and may require only minimal 25 treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research 30 participant. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. A 35 82 208 In some embodiments, the subject does not suffer any severe adverse events as a result ofadministration of petrelintide. Reduced calorie diet and increased physical activity 5 It is well-known that a reduced calorie diet and / or increased physical activity can lead to weight loss. In the context of medical treatment, a physician may prescribe a reduced calorie diet and / or increased physical activity for a subject seeking to lose weight. In a non- therapeutic context, a subject may consume a reduced calorie diet or undertake increased physical activity to lose weight. 10 Hence, petrelintide may be administered to a subject in combination with a reduced calorie diet and increased physical activity, in order to effectively promote weight loss. Thus, in some embodiments, the method comprises administering petrelintide in 15 combination with a reduced calorie diet and increased physical activity. In some embodiments, the method comprises administering petrelintide in combination with a reduced calorie diet or increased physical activity. In some embodiments, the method comprises administering petrelintide in combination with a reduced calorie diet and / or increased physical activity. 20 calorie diet. Thus, in some embodiments, the subject consumes a reduced calorie diet. the subject contains fewer calories relative to 25 refers to a diet which puts the subject in a calorie deficit. In other words, a reduced calorie diet is a diet wherein the subject consumes fewer calories than they use is a day (i.e., total daily calorific intake is less than total daily energy expenditure). It is well-known in the art that being in calorie deficit results in weight loss. Calorie deficit is typically expressed as a30 deficit of a specific value of kilocalories per day (i.e., kcal / day deficit). In some embodiments, the reduced calorie diet is approximately 500 kcal / day deficit. The reduced calorie diet may be prescribed by a physician, such as in the f 35 83 208 physical activity. Thus, in some embodiments, the subject performs increased physical activity. 5 to undertaking the method of the invention. In some embodiments, increased physical activity is at least 150 minutes of physical activity per week. The increased physical activity may be prescribed by a physician, such as in the form of an 10 Non-incretin peptide hormones The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease15 linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the subject.20 In some embodiments, the invention provides a method of treating overweight, overweight inthe presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a human female subject,the method comprising administering a non-incretin peptide hormone or a pharmaceutically25 acceptable salt thereof to the subject.which function with insulin to stimulate a decrease in blood glucose levels. Amylin and its analogues are not considered to be incretins. Thus, petrelintide is a non-incretin peptide 30 hormone. The non-incretin peptide hormone as used in the invention may be in the form of apharmaceutically acceptable salt. Thus, any reference herein to a non-incretin peptide hormone encompasses pharmaceutically acceptable salts thereof.35 In some embodiments, the disease linked to overweight, overweight in the presence of at least one weight-related comorbid condition, obesity or to diabetes is selected from the 84 208 group consisting of: obesity-linked inflammation, obesity-linked gallbladder disease, obesity- induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, Alzh -diabetes, insulinresistance syndrome, impaired glucose tolerance (IGT), disease states associated with 5 elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis (NASH), kidney failure, arteriosclerosis,macrovascular disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral10 artery disease and stroke. In some embodiments, the invention provides a method of reducing body weight, reducingexcess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human15 female subject, the method comprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the subject.In some embodiments, the method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing20 appetite, increasing satiety or promoting weight loss, in a human female subject is a non-therapeutic method. In some embodiments, the method of reducing body weight, reducing excess body weight, inhibiting weight gain, maintaining weight reduction long term, maintaining weight reduction25 long term, reducing food intake, reducing appetite, increasing satiety or promoting weightloss, in a human female subject is a cosmetic method.In some embodiments, the non-incretin peptide hormone is amylin or an amylin analogue. Insome embodiments, the non-incretin peptide hormone is an amylin analogue. In some30 embodiments, the non-incretin peptide hormone is petrelintide. Thus, the invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or adisease linked to overweight, obesity or diabetes, or of reducing body weight, reducing35 excess body weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human85 208 female subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject.Dose of non-incretin peptide hormone 5 In some embodiments, the method comprises administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the subject at a dose of 2.4 mg or more. Insome embodiments, the method comprises administering a non-incretin peptide hormone or apharmaceutically acceptable salt thereof to the subject at a dose of about 2.4 mg or more.The non-incretin peptide hormone or a pharmaceutically acceptable salt thereof may be10 administered to the subject at any of the doses described herein. The non-incretin peptidehormone may be administered to the subject at any of the doses of petrelintide described herein. In some embodiments, the dose is 3.0 mg or more, 3.6 mg or more, 4.0 mg or more, 4.8 mg15 or more, 5.0 mg or more, 6.0 mg or more, 7.0 mg or more, 7.5 mg or more, 8.0 mg or more, or 9.0 mg or more. In some embodiments, the dose is about 2.5 mg or more, about 2.6 mg or more, about 2.7mg or more, about 2.8 mg or more, about 2.9 mg or more, about 3.0 mg or more, about 3.120 mg or more, about 3.2 mg or more, about 3.3 mg or more, about 3.4 mg or more, about 3.5mg or more, about 3.6 mg or more, about 3.7 mg or more, about 3.8 mg or more, about 3.9mg or more, about 4.0 mg or more, about 4.1 mg or more, about 4.2 mg or more, about 4.3mg or more, about 4.4 mg or more, about 4.5 mg or more, about 4.6 mg or more, about 4.7mg or more, about 4.8 mg or more, about 4.9 mg or more, about 5.0 mg or more, about 5.525 mg or more, about 6.0 mg or more, about 6.5 mg or more, about 7.0 mg or more, about 7.5 mg or more, about 8.0 mg or more, about 8.5 mg or more, or about 9.0 mg or more. In some embodiments, the dose is more than 2.4 mg, more than 3.0 mg, more than 4.0 mg,more than 4.8 mg, more than 5.0 mg, more than 6.0 mg, more than 7.0 mg, more than 7.530 mg, or more than 8.0 mg. In some embodiments, the dose is more than about 2.4 mg, more than about 2.5 mg, morethan about 2.6 mg, more than about 2.7 mg, more than about 2.8 mg, more than about 2.9mg, more than about 3.0 mg, more than about 3.1 mg, more than about 3.2 mg, more than35 about 3.3 mg, more than about 3.4 mg, more than about 3.5 mg, more than about 3.6 mg,more than about 3.7 mg, more than about 3.8 mg, more than about 3.9 mg, more than about4.0 mg, more than about 4.1 mg, more than about 4.2 mg, more than about 4.3 mg, more86 208 than about 4.4 mg, more than about 4.5 mg, more than about 4.6 mg, more than about 4.7mg, more than about 4.8 mg, more than about 4.9 mg, more than about 5.0 mg, more thanabout 5.5 mg, more than about 6.0 mg, more than about 6.5 mg, more than about 7.0 mg,more than about 7.5 mg, more than 8.0 mg, or more than about 8.5 mg. 5 In some embodiments, the dose is at most 10.0 mg, or at most about 9.5 mg, or at most 9.0mg. In some embodiments, the dose is from 2.4 mg to 10.0 mg, from 3.6 mg to 10.0 mg, from 4.010 mg to 10.0 mg, from 4.8 mg to 10.0 mg, from 6.0 mg to 10.0 mg, from 7.5 mg to 10.0 mg,from 9.0 mg to 10.0 mg, from 2.4 mg to 9.0 mg, from 3.6 mg to 9.0 mg, from 4.0 mg to 9.0 mg, from 4.8 mg to 9.0 mg, from 6.0 mg to 9.0 mg, from 6.1 mg to 9.0 mg, from 6.5 mg to 9.0 mg, from 7.0 mg to 9.0 mg, from 7.5 mg to 9.0 mg, from 8.0 mg to 9.0 mg, or from 8.5mg to 9.0 mg. 15 In some embodiments, the dose is from about 2.4 mg to about 10.0 mg, from about 2.5 mgto about 10.0 mg, from about 2.6 mg to about 10.0 mg, from about 2.7 mg to about 10.0 mg,from about 2.8 mg to about 10.0 mg, from about 2.8 mg to about 10.0 mg, from about 2.9 mgto about 10.0 mg, from about 3.0 mg to about 10.0 mg, from about 3.1 mg to about 10.0 mg,20 from about 3.2 mg to about 10.0 mg, from about 3.3 mg to about 10.0 mg, from about 3.4 mgto about 10.0 mg, from about 3.5 mg to about 10.0 mg, from about 3.6 mg to about 10.0 mg,from about 3.7 mg to about 10.0 mg, from about 3.8 mg to about 10.0 mg, from about 3.9 mgto about 10.0 mg, from about 4.0 mg to about 10.0 mg, from about 4.1 mg to about 10.0 mg,from about 4.2 mg to about 10.0 mg, from about 4.3 mg to about 10.0 mg, from about 4.4 mg25 to about 10.0 mg, from about 4.5 mg to about 10.0 mg, from about 4.6 mg to about 10.0 mg,from about 4.7 mg to about 10.0 mg, from about 4.8 mg to about 10.0 mg, from about 4.9 mgto about 10.0 mg, from about 5.0 mg to about 10.0 mg, from about 5.5 mg to about 10.0 mg,from about 6.0 mg to about 10.0 mg, from about 7.0 mg to about 10.0 mg, from about 7.5 mg to about 10.0 mg, from about 8.0 mg to about 10.0 mg, from about 8.5 mg to about 10.0 mg,30 or from about 9.0 mg to about 10.0 mg. In some embodiments, the dose is from about 2.4 mg to about 9.0 mg, from about 2.5 mg toabout 9.0 mg, from about 2.6 mg to about 9.0 mg, from about 2.7 mg to about 9.0 mg, fromabout 2.8 mg to about 9.0 mg, from about 2.8 mg to about 9.0 mg, from about 2.9 mg to35 about 9.0 mg, from about 3.0 mg to about 9.0 mg, from about 3.1 mg to about 9.0 mg, fromabout 3.2 mg to about 9.0 mg, from about 3.3 mg to about 9.0 mg, from about 3.4 mg toabout 9.0 mg, from about 3.5 mg to about 9.0 mg, from about 3.6 mg to about 9.0 mg, from87 208 about 3.7 mg to about 9.0 mg, from about 3.8 mg to about 9.0 mg, from about 3.9 mg toabout 9.0 mg, from about 4.0 mg to about 9.0 mg, from about 4.1 mg to about 9.0 mg, fromabout 4.2 mg to about 9.0 mg, from about 4.3 mg to about 9.0 mg, from about 4.4 mg toabout 9.0 mg, from about 4.5 mg to about 9.0 mg, from about 4.6 mg to about 9.0 mg, from5 about 4.7 mg to about 9.0 mg, from about 4.8 mg to about 9.0 mg, from about 4.9 mg toabout 9.0 mg, from about 5.0 mg to about 9.0 mg, from about 5.5 mg to about 9.0 mg, fromabout 6.0 mg to about 9.0 mg, from about 6.1 mg to about 9.0 mg, from about 6.5 mg to about 9.0 mg, from about 7.0 mg to about 9.0 mg, from about 7.5 mg to about 9.0 mg, fromabout 8.0 mg to about 9.0 mg, or from about 8.5 mg to about 9.0 mg. 10 In some embodiments, the dose is more than 2.4 mg up to 10.0 mg, more than 3.6 mg up to10.0 mg, more than 4.0 mg up to 10.0 mg, more than 4.8 mg up to 10.0 mg, more than 6.0 mg up to 10.0 mg, more than 7.5 mg up to 10.0 mg, more than 2.4 mg up to 9.0 mg, more than 3.6 mg up to 9.0 mg, more than 4.0 mg up to 9.0 mg, more than 4.8 mg up to 9.0 mg,15 more than 6.0 mg up to 9.0 mg, or more than 7.5 mg up to 9.0 mg. In some embodiments, the dose is more than about 2.4 mg up to about 10.0 mg, more thanabout 2.5 mg up to about 10.0 mg, more than about 2.6 mg up to about 10.0 mg, more thanabout 2.7 mg up to about 10.0 mg, more than about 2.8 mg up to about 10.0 mg, more than20 about 2.9 mg up to about 10.0 mg, more than about 3.0 mg up to about 10.0 mg, more thanabout 3.1 mg up to about 10.0 mg, more than about 3.2 mg up to about 10.0 mg, more thanabout 3.3 mg up to about 10.0 mg, more than about 3.4 mg up to about 10.0 mg, more thanabout 3.5 mg up to about 10.0 mg, more than about 3.6 mg up to about 10.0 mg, more thanabout 3.7 mg up to about 10.0 mg, more than about 3.8 mg up to about 10.0 mg, more than25 about 3.9 mg up to about 10.0 mg, more than about 4.0 mg up to about 10.0 mg, more thanabout 4.1 mg up to about 10.0 mg, more than about 4.2 mg up to about 10.0 mg, more thanabout 4.3 mg up to about 10.0 mg, more than about 4.4 mg up to about 10.0 mg, more thanabout 4.5 mg up to about 10.0 mg, more than about 4.7 mg up to about 10.0 mg, more thanabout 4.8 mg up to about 10.0 mg, more than about 4.9 mg up to about 10.0 mg, more than30 about 5.0 mg up to about 10.0 mg, more than about 5.5 mg up to about 10.0 mg, more thanabout 6.0 mg up to about 10.0 mg, more than about 6.5 mg up to about 10.0 mg, more thanabout 7.0 mg up to about 10.0 mg, more than about 7.5 mg up to about 10.0 mg, more thanabout 8.0 mg up to about 10.0 mg, more than about 8.5 mg up to about 10.0 mg, or morethan about 9.0 mg up to about 10.0 mg.35 In some embodiments, the dose is more than about 2.4 mg up to about 9.0 mg, more thanabout 2.5 mg up to about 9.0 mg, more than about 2.6 mg up to about 9.0 mg, more than88 208 about 2.7 mg up to about 9.0 mg, more than about 2.8 mg up to about 9.0 mg, more thanabout 2.9 mg up to about 9.0 mg, more than about 3.0 mg up to about 9.0 mg, more thanabout 3.1 mg up to about 9.0 mg, more than about 3.2 mg up to about 9.0 mg, more thanabout 3.3 mg up to about 9.0 mg, more than about 3.5 mg up to about 9.0 mg, more than5 about 3.6 mg up to about 9.0 mg, more than about 3.7 mg up to about 9.0 mg, more thanabout 3.8 mg up to about 9.0 mg, more than about 3.9 mg up to about 9.0 mg, more thanabout 4.0 mg up to about 9.0 mg, more than about 4.1 mg up to about 9.0 mg, more thanabout 4.2 mg up to about 9.0 mg, more than about 4.3 mg up to about 9.0 mg, more thanabout 4.4 mg up to about 9.0 mg, more than about 4.5 mg up to about 9.0 mg, more than10 about 4.6 mg up to about 9.0 mg, more than about 4.7 mg up to about 9.0 mg, more thanabout 4.8 mg up to about 9.0 mg, more than about 4.9 mg up to about 9.0 mg, more thanabout 5.0 mg up to about 9.0 mg, more than about 5.5 mg up to about 9.0 mg, more thanabout 6.0 mg up to about 9.0 mg, more than about 6.5 mg up to about 9.0 mg, more thanabout 7.0 mg up to about 9.0 mg, more than about 7.5 mg up to about 9.0 mg, or more than15 about 8.0 mg up to about 9.0 mg.In some embodiments, the dose is 2.4 mg, 2.5 mg, 3.6 mg, 4.0 mg, 4.8 mg, 5.0 mg, 6.0 mg,7.0 mg, 7.5 mg or 9.0 mg.20 In some embodiments, the dose is about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg,about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, about 3.2 mg, about 3.3 mg, about 3.4 mg, about 3.5 mg, about 3.6 mg, about 3.7 mg, about 3.8 mg, about 3.9 mg, about 4.0 mg, about 4.1 mg, about 4.2 mg, about 4.3 mg, about 4.4 mg, about 4.5 mg, about 4.6 mg, about 4.7 mg, about 4.8 mg, about 4.9 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about25 6.5 mg, about 7.0 mg, about 7.5 mg, about 8.0 mg, about 8.5 mg, or about 9.0 mg.The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body30 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 4.8 mg.35 The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body89 208 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 4.8 mg or more.5 The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake,10 reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 5.0 mg.The invention provides a method of treating overweight, overweight in the presence of at15 least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt20 thereof to the human female subject at a dose of 5.0 mg or more.The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body25 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 6.0 mg.30 The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,35 the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 6.0 mg or more.90 208 The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, 5reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 7.0 mg.The invention provides a method of treating overweight, overweight in the presence of at10 least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess bodyweight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt15 thereof to the human female subject at a dose of 7.0 mg or more.The invention provides a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a diseaselinked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body20 weight, inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject,the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the human female subject at a dose of 9.0 mg.25 Administration of non-incretin peptide hormone In some embodiments, the method comprises administering a non-incretin peptide hormoneor a pharmaceutically acceptable salt thereof to the subject once weekly.In some embodiments, the non-incretin peptide hormone or a pharmaceutically acceptable30 salt thereof is administered subcutaneously, such as via subcutaneous injection.In some embodiments, the non-incretin peptide hormone or a pharmaceutically acceptablesalt thereof is administered in the form of a composition further comprising one or morepharmaceutically acceptable excipients. In some embodiments, the composition is in the35 form of a solution, such as an aqueous solution. 91 208 Adverse events from a non-incretin peptide hormoneIn some embodiments, the human female subject experiences fewer or the same number of gastrointestinal adverse events compared to a corresponding human male subject administered the non-incretin peptide hormone or a pharmaceutically acceptable salt5 thereof. has been administered the non-incretin peptide hormone according to the same dosage regimen as the female human subject. For example, the corresponding human male subject10 has been administered the non-incretin peptide hormone at the same dose, at the same intervals and for the same overall period as the female human subject In some embodiments, the human female subject experiences gastrointestinal adverseevents of the same or lesser severity compared to a corresponding human male subject15 administered the non-incretin peptide hormone. In some embodiments, the human female subject does not suffer any severe gastrointestinaladverse events as a result of administration of the non-incretin peptide hormone. In someembodiments, the gastrointestinal adverse event is selected from diarrhea and constipation.20 In some embodiments, the gastrointestinal adverse event is diarrhea. In some embodiments, the gastrointestinal adverse event is constipation. Weight loss from a non-incretin peptide hormone In some embodiments, body weight of the human female subject is decreased by 2% or25 more, 2.5% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more, 5.5% or more, 6% or more, 6.5% or more, 7% or more, 7.5% or more, 8% or more, 8.5% or more, 9% or more, 9.5% or more, or 10% or more relative to their body weight at the start of treatment with the non-incretin peptide hormone. 30 In some embodiments, body weight of the human female subject is decreased by 2% or more, 2.5% or more, 3.5% or more, 4% or more, 4.5% or more, 5% or more, 5.5% or more, 6% or more, 6.5% or more, 7% or more, 7.5% or more, 8% or more, 8.5% or more, 9% ormore, 9.5% or more, or 10% or more relative to their body weight at the start of treatment with the non-incretin peptide hormone after about 16 weeks treatment with the non-incretin35 peptide hormone. 92 208 In some embodiments, the body weight of the human female subject is decreased by about2% or more, about 2.5% or more, about 3.5% or more, about 4% or more, about 4.5% or more, about 5% or more, about 5.5% or more, about 6% or more, about 6.5% or more, about 7% or more, about 7.5% or more, about 8% or more, about 8.5% or more, about 9% or5 more, about 9.5% or more, or about 10% or more relative to their body weight at the start of treatment with the non-incretin peptide hormone. In some embodiments, body weight of the human female subject is decreased proportionallymore than the body weight of a corresponding human male subject administered the non-10 incretin peptide hormone. the non-incretin peptide hormone according to the same dosage regimen as the female human subject. 15 weight of the subject, before treatment with the non-incretin hormone) to account for different starting body weights between men and women. Proportional body weight may be expressed as the difference in percentage body weight decrease between the human female subject and the corresponding human male subject. Thus, in some embodiments, body weight of the human female subject is decreased by at least 1% more than the body weight20 of the human male subject administered the non-incretin peptide hormone, such as by atleast 1.5% more, at least 2% more, at least 2.5% more, at least 3% more, at least 3.5%more, at least 4% more, at least 5% more, at least 6% more, at least 7% more, or at least 8% more.25 In some embodiments, the body weight of the human female subject is decreased by at least1% more than the body weight of the human male subject administered the non-incretinpeptide hormone, such as by at least about 1.5% more, at least about 2% more, at least about 2.5% more, at least about 3% more, at least about 3.5% more, at least about 4% more, at least about 5% more, at least about 6% more, at least about 7% more, or at least30 about 8% more. In some embodiments, body weight of the human female subject is decreased by at least 1% more than the body weight of the human male subject administered the non-incretinpeptide hormone, such as by at least 1.5% more, at least 2% more, at least 2.5% more, at 35 least 3% more, at least 3.5% more, at least 4% more, at least 5% more, at least 6% more, at least 7% more, or at least 8% more after about 16 weeks treatment with the non-incretinpeptide hormone, such as e.g., petrelintide. 93 208 EXAMPLES The following examples are provided to illustrate preferred aspects of the invention and are not intended to limit the scope of the invention. 5 Materials & Methods Drug Petrelintide was used in all three examples in a formulation comprising petrelintide 4 mg / mLand placebo as shown in Table 1 below.10 Table 1: Formulation parameters Manufacturing of the above Drug Product and matching placebo was performed by Rechon Life Science AB, Limhamn, Sweden on behalf of Zealand Pharma A / S. Klifo A / S, Glostrup,15 Denmark is responsible for secondary packaging and labelling of Drug Product and matching placebo. Adverse events (AE) During all three studies (Example 1-3), all events meeting the definition of an AE were20 collected and reported from the first trial-related activity after the participant has signed theinformed consent until the end of the post-treatment follow-up period. At each contact with the site (visit or telephone, excluding safety visits, where the participant were not seeing theInvestigator or sites staff (e.g. visits to the laboratory)) the participant were asked about AEs.All AEs, either observed by the Investigator or reported by the participant, were recorded by25the Investigator and evaluated. The Investigator recorded the diagnosis, if possible. If no diagnosis could be made the Investigator recorded each sign and symptom as individual AEs. 94 208 The maximum intensity (severity) of all AEs were assessed by the investigator and documented. Severity was graded when the AE outcome was known, in accordance with the following: 5 Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, 10 causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. A 15 Example 1: Phase 1a clinical trial assessing single ascending doses A first-in-human, randomized, single ascending dose (SAD) trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide administered to healthy20 participants was performed.Subjects were healthy male participants that were of normal weight and overweight (BMI:21.0-29.9 kg / m2).25Trial design The trial was a single-centre, randomised, double-blind, placebo-controlled, single ascending dose trial in normal weight and overweight but otherwise healthy male participants randomised to petrelintide or placebo (randomisation ratio 3:1; n= 6 and n= 2) within eachcohort.56 participants were allocated to the following seven ascending dose levels: 0.04,300.08, 0.16, 0.35, 0.7, 1.4, 2.4 mg with subcutaneous (s.c.) dose administration as shown in Figure 1. An i.v. cohort of eight participants was allocated to one dose level of 0.35 mg.A sentinel dosing approach (sequential dosing) was applied within cohorts. The entire observation period comprised 50 days starting with an in-house stay (from Day -1 to Day 8), 35 where discharge was performed on Day 8, followed by six ambulatory visits and an End of Trial (EOT) Visit on Day 50. 95 208 A blinded evaluation of each cohort was performed by a Trial Safety Group (TSG) to determine whether the trial would progress to the next dose level based on the stoppingrules applied for the trial. 5 Participants received a single dose which consisted of either 0.04 mg, 0.08 mg, 0.16 mg,0.35 mg, 0.7 mg, 1.4 mg, or 2.4 mg of the amylin analogue or placebo administered subcutaneously, or 0.35 mg administered intravenously as shown in Table 2 below.10 Table 2: Dose and cohort parameters All demographics were balanced across cohorts of healthy participants. The baseline characteristics of the participants are shown below.15 Table 3: Participant parameters 96 208 Results The mean half-life of petrelintide was approximately 10 days (Figure 2). A half-life of approximately 10 days is suitable for once weekly dosing. 5 Participants receiving petrelintide exhibited a dose-dependent, consistent and sustainedreduction in bodyweight (Figure 3). In particular, after 1 week of observation, mean body weight decreased by 0.6%, 2.6%, 3.6%, and 4.2% from baseline following a single dose of placebo, 0.7, 1.4 and 2.4 mg, respectively. 10 Petrelintide was well tolerated in single doses of up to 2.4 mg, with no serious or severeadverse events (AEs) and no withdrawals. The number and severity of gastrointestinal AEs increased with dose. The most frequent AEs were decreased appetite, nausea and vomiting; most AEs were mild and transient. The results can be seen in Tables 10, 11a and 11b in15 Example 3. Furthermore, no anti-drug antibodies were detected. The consistent dose-dependent reduction in bodyweight observed is indicative of the20 suitability of petrelintide for the treatment of obesity or to aid weight loss.Example 2: Phase 1 clinical trial assessing multiple ascending doses (Part 1) A first-in-human, randomized, multiple ascending dose (MAD) trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide administered to healthy25 participants was performed.Participants were healthy male participants that were of normal weight and overweight (BMI:21.0-29.9 kg / m2).30Trial design The trial was a single-centre, randomised and double-blind within cohorts, placebo- controlled, sequential multiple ascending dose trial in normal weight and overweight but 97 208 otherwise healthy participants randomised to petrelintide or placebo (randomisation ratio 7:3)within each cohort. A total of 20 participants (mean body weight of 82 kg and BMI of 25.4kg / m2) were allocated to the following two ascending dose levels of 6 once weeklyadministrations of the amylin analogue or placebo: 0.6 or 1.2 mg with subcutaneous (s.c.)5 dose administration, as shown in Figure 4. A sentinel dosing approach (sequential dosing) was applied within cohorts. The entire observation period comprised 92 days starting with a first in-house stay (from Day -1 to Day 2), where discharge was planned for Day 2, followed by one ambulatory visit (Day 5), a 10 second in-house stay (from Day 8 to Day 12), where discharge was planned for Day 12, a third in-house stay (from Day 15 to Day 19), where discharge was planned for Day 19, a fourth in-house stay (from Day 22 to Day 24), where discharge was planned for Day 24, followed by one ambulatory visit (Day 26), a fifth in-house stay (from Day 29 to Day 31), where discharge was planned for Day 31, a sixth in-house stay (from Day 36 to Day 38), 15 where discharge was planned for Day 38, followed by five ambulatory visit (Day 40, Day 43, Day 50, Day 64 and Day 75), and an End of Trial (EOT) Visit on Day 92.A blinded evaluation of each cohort was performed by a Trial Safety Group (TSG) to determine whether the trial would progress to the next dose level based on the stopping20 rules specified applied for the trial. Participants received a single dose once weekly, which consisted of either 0.6 mg or 1.2 mgof the amylin analogue or placebo, administered subcutaneously, as shown in Table 4 below. 25 Table 4: Dose and cohort parameters All demographics were balanced across cohorts of healthy subjects. The baseline characteristics of the subjects are shown in Table 5 below.30 Table 5: Participants parameters 98 208 Two participants did not receive the 6th dose. All 20 randomized participants completed thetrial. 5 Results In accordance with the trial design, as detailed above, data pertaining to successive dose cohorts (i.e. cohorts receiving an ascending dose relative to the preceding cohort) became available sequentially.10 Participants receiving petrelintide exhibited a mean body weight decrease of 0.4%, 5.3% and5.1% from baseline following six weekly doses of placebo, 0.6 mg and 1.2 mg, respectively. Figure 5 shows individual and mean (bold line) weight loss during the trial.Table 6: Mean weight change one week after the sixth dose of placebo petrelintide 15 Petrelintide was well tolerated, with no serious or severe adverse events (AEs) and no withdrawals. The most frequent related AEs were decreased appetite, early satiety, food aversion and nausea, all were mild and transient. Nausea was experienced by only three participants treated with petrelintide, with one also reporting vomiting. No injection site20 reactions were reported, and no anti-drug antibodies detected. The results can be seen inTables 10, 11a and 11b of Example 3.Treatment with six doses of petrelintide was safe and well tolerated and resulted inmeaningful reductions in body weight. The most common related AEs were related to the GI 25 system, were all mild and most had onset within 2 days of the first dose. These data confirm the observations of weight loss after single doses of the amylin analogue and are similar to weight loss observed after 6 weeks with other weight loss treatments. Cohorts with longer treatment duration and dose up-titration exploring amylin analogue doses above 1.2 mg are ongoing to further assess the clinical potential of petrelintide. 30 99 208 Example 3: Phase 1 clinical trial assessing multiple ascending doses (Part 2) Amultiple ascending dose (MAD) trial assessing safety, tolerability, pharmacokinetics, andpharmacodynamics of petrelintide administered to healthy participants was performed.5 Participants were healthy male participants or female participants of non-childbearingpotential that were overweight and obese, but otherwise healthy, with a Body Mass Index(BMI) between 27.0 and 39.9 kg / m2. Trial design 10 Part 2 of the MAD trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial in overweight and obese, but otherwise healthy participants, randomised to petrelintide or placebo (randomisation ratio3:1) within each cohort. Use of dose up-titration will be explored in order to reach higher exposure of petrelintide. 15 After six once-weekly doses of petrelintide of the maintenance dose for a given cohort,steady state was achieved. Subjects were allocated to the following three cohorts targetingthree different maintenance doses with 16 once-weekly subcutaneous (s.c.) dose administrations of petrelintide or placebo (Figure 6):20 Cohort 1: 0.6, 0.6, 1.2, 1.2 mg followed by a maintenance dose of 2.4 mg for 12weeks. Cohort 2: 0.6, 0.6, 1.2, 1.2, 2.4, 2.4, 3.6, 3.6 mg followed by a maintenance dose of 4.8 mg for 8 weeks.25 Cohort 3: 1.0, 1.0, 2.0, 2.0, 4.0, 4.0, 6.0, 6.0, 7.5, 7.5 mg followed by a maintenancedose of 9.0 mg for 6 weeks.48 participants were randomised to the three cohorts of 16 participants, where subjects in a3:1 ratio with 12 participants received petrelintide and 4 participants received placebo in30 each cohort. The total observation period was 26 weeks started with an initial in-house stay (from Day -1 to Day 2), with scheduled discharge on Day 2, followed by 3 ambulatory visits for once- weekly dosing, and subsequent 13 in-house visits of 1-4 overnight stays depending on the 35 dose level. The 16 once-weekly dosings (Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99 and 106) were followed by six ambulatory visits (Day 108, 110, 113±1, 120±1, 134±1, 148±1) for the 1stcohort and five ambulatory visits (Day 110, 113±1, 120±1, 134±1, 148±1) 100 208 for the 2ndand 3rdcohort and an End of Trial (EOT) Visit on Day 169±2. A blinded evaluation of each cohort were performed by a Trial Safety Group (TSG) with data up to the predose assessments of the 5th maintenance dose (Cohort 1: Day 57 and Cohort 2: Day 85 andCohort 3: Day 99) to determine if the current dose level is considered safe and if dose 5 escalation could continue in the next cohort based on the stopping rules. Participants received a single dose once weekly, which consisted of either 2.4, 4.8 or 9.0 mgpetrelintide or placebo, administered subcutaneously, as shown in Table 7 below.10 Table 7: Dose and cohort parameters All demographics were balanced across cohorts of healthy participants. The baseline characteristics of the subjects are shown in Table 8a below.15 Table 8a: Participant parameters 48 participants having a median body weight of 92 kg and BMI of 29.1 kg / m2 participated inthe trial. are presented in Table 8b below.Each participant was administered the same dose of petrelintide as the rest of their cohort 20 (i.e., 2.4 mg, 4.8 mg or 9.0 mg, depending on their cohort) regardless of their individual weight. Table 8b: Participant age, BMI and weight 101 208 One participant in the 9.0 mg cohort discontinued due to adverse events experienced when administered doses of 2.0 mg. One other participant in the 9.0 mg cohort and one participantin the 4.8 mg cohort discontinued for other reasons. Hence, 45 randomized participants 5 completed the treatment period. Results In accordance with the trial design, as detailed above, data pertaining to successive dose cohorts (i.e. cohorts receiving an ascending dose relative to the preceding cohort) became 10 available sequentially. Participants receiving petrelintide exhibited a body weight decrease of 1.7%, 4.8%, 8.6%and 8.3% from baseline following sixteen weekly doses of placebo, 2.4 mg, 4.8 mg and 9.0mg, respectively. 15 Table 9: Mean weight change one week after the sixteenth dose of placebo or petrelintide Petrelintide was well tolerated, with no serious or severe adverse events (AEs). The mostfrequently reported treatment-emergent adverse events (TEAEs) by petrelintide treated20 participants were decreased appetite, injection site reactions, nasopharyngitis, nausea, andheadache, of which only one event of nausea was moderate; the remaining were mild andtransient. Nausea was only experienced by 2, 2, 4 and 4 participants following sixteenweekly doses of placebo, 2.4 mg, 4.8 mg or 9.0 mg petrelintide, respectively, with only one participant also reporting two events of vomiting. The results are shown in Figure 7 and the25 below Tables 10, 11a and 11b, where N = number of participants, % = percentage ofparticipants having an AE, and E = number of events.102 Table 10: AE severity

[0002]

[0003] 208

[0004] Table 11a: AEs: Gastrointestinal and metabolism / nutrition disorders

[0005]

[0006] 208 Summary of results Example 3The second part of a randomized, double blind, placebo controlled trial to assess safety,pharmacokinetics, and pharmacodynamics of sixteen weekly subcutaneous injections of petrelintide in healthy lean and overweight participants has been concluded. A total of 485 participants (median body weight of 92 kg and BMI of 29.1 kg / m2) were randomized topetrelintide or placebo (12:4) within three dose cohorts. The mean body weight decreased by 1.7%, 4.8% 8.6% and 8.3% from baseline following sixteen weekly doses of placebo, 2.4 mg, 4.8 mg and 9.0 mg respectively.10 Petrelintide was well tolerated, with no serious or severe adverse events (AEs) and one withdrawal due to adverse events. The most frequently reported TEAEs by petrelintidetreated participants were decreased appetite, injection site reactions, nasopharyngitis, nausea, headache. Most TEAEs reported by petrelintide treated participants were mild, only 15 5 were moderate and of those only 2 judged to be causally related (1 participant starting at 1.0 mg, discontinued due to GI AEs). All injection site reactions were mild, 2 participantstreated with petrelintide reported the majority of events (63%). Nausea mainly had an onset in the dose escalation phase.20 Treatment with sixteen doses of petrelintide was safe and well tolerated and resulted inmeaningful reductions in body weight, with the greatest weight loss being observed in those cohorts treated with a maintenance dose higher than 2.4 mg such as 4.8 or 9.0 mg. The most common related AEs were related to the GI system, most were mild and transient.25 The results in Table 9 show that the effect of petrelintide on body weight reduction continuedto improve also through a maintenance dose higher than 2.4 mg such as 4.8 or 9.0 mg once weekly. Body weight reduction for the maintenance dose of 2.4 mg was similar to that of the0.6 and 1.2 mg body weight reduction in Example 2, whilst 4.8 and 9.0 mg maintenance doses gave desirable additional body weight reduction. We therefore consider doses higher30 than 2.4 mg as high doses and 2.4 mg and below as low doses. Surprisingly, the results inTables 10 and 11a show that in terms of the number of participants experiencinggastrointestinal events was relatively lower when administering these two high dosages which resulted in almost 10-fold higher exposure in terms of Cmax and AUC compared toExample 1. The severity of GI adverse events was also not increased with increasing35 multiple doses of 4.8 and 9.0 mg (2 moderate events) compared to the single doses of 1.4 and 2.4 mg (11 moderate events). Upon comparison of the results relating to GI AEs thesedecreases surprisingly were relatively lower than the improvement in body weight reduction. 107 208 Table 11b shows that all types of adverse events are generally low in frequency in subjectsadministered petrelintide and do not markedly increase in frequency with increased dose of petrelintide. 5 Diarrhea is a common side-effect of peptide hormone weight loss drugs. However, the incidence of diarrhea was low at all doses of petrelintide. In particular, in the MAD trial part 2,only two participants (out of twelve participants) administered petrelintide at a dose of 2.4 mg reported a single incident of diarrhea each. No incidents of diarrhea were reported by any participants in the cohorts administered petrelintide at 4.8 mg or 9.0 mg. Thus, in total, only 2 10 participants out of a total of 36 participants (i.e., 5% of participants) to whom petrelintide was administered in the MAD trial part 2 reported an incidence of diarrhea. Thus, the incidence of diarrhea specifically surprisingly did not increase at all with increasing dose of petrelintide. Figure 7 shows the percentage body weight change of individual male (grey lines) and15 female (black lines) participants in each cohort of the MAD trial part 2. The cohorts are presented in separate panels as follows: 2.4 mg petrelintide in the top-left (two female participants), 4.8 mg petrelintide in the top-right (three female participants), 9.0 mgpetrelintide in the bottom-left (three female participants), placebo in the bottom-right (two female participants). 20 The participants with greatest % weight loss during the 16-week period in which petrelintide was administered were female. This suggest that petrelintide may be particularly effective in reducing body weight of female subjects. In particular, in the 2.4 mg cohort, the participantwith greatest % weight loss during the 16-week administration period was female. In the 4.8 25 mg cohort, the two participants with greatest % weight loss during the 16-week administration period were female, and these two participants remained the participants with greatest % weight loss up to 10 weeks after the administration period. In the 9.0 mg cohort, the two participants with greatest % weight loss during the 16-week administration period were female, and one of these participants remained the participant with greatest % weight 30 loss up to 10 weeks after the administration period. Notably, each cohort contained only 2 or 3 female participants (out of 12 participants in each cohort). That females subjects were under-represented in the cohort but consistently had the greatest % weight loss reinforces the suggestion that petrelintide may be particularly effective in reducing body weight of female subjects. 35 In summary, these results show, that it is possible to administer petrelintide at maintenance doses higher than 2.4 mg as seen for doses such as 4.8 mg and 9.0 mg in Example 3 108 208 resulting in improved weight loss without increasing the level of gastrointestinal events. Due to this unexpected, good ratio between body weight reduction and gastrointestinal adverseevents it is possible to dose petrelintide at higher maintenance doses of greater than 2.4 mgwithout risking patient safety. 5 Example 4: Analysis of Phase 1 clinical trial assessing multiple ascending doses (Part2) to determine effects by sex.The results from the Phase 1 clinical trial assessing multiple ascending doses (part 2), described in Example 3, suggested that petrelintide might be particularly effective in10 reducing body weight of female subjects. The effects by sex were explored post hoc, and aredescribed below. Trial design Full trial design can be found in the trial design section of Example 3. Of the healthy15 participants (N=48) 79% were men and 21% were women. Adverse events (AEs), body weight (BW) and waist circumference (WC) by sex were analyzed across treatment groups. The pooled placebo group included 2 women. Results 20 At 16 weeks, mean body weight decreased by 4.8%, 8.6% and 8.3% for participants receiving 2.4 mg, 4.8 mg and 9.0 mg of petrelintide, respectively, compared to 1.7% for thepooled placebo. Similarly, waist circumference decreased by 5.0 cm, 7.2 cm and 7.6 cm for participants receiving 2.4 mg, 4.8 mg and 9.0 mg of petrelintide, respectively, compared to1.9 cm for the pooled placebo. A consistently greater treatment response (body weight25 reduction and waist circumference reduction) was observed in women across three petrelintide treated cohorts, as shown in Figure 8 and Table 12 below (BW = body weight,WC = waist circumference and N = number of participants).Table 12: Change in body weight and waist circumference from baseline to week 16 in 30 petrelintide treated participants (treatment completers, total and by sex) 109 208 The incidence of gastrointestinal (GI) AEs was low, with only one treatment discontinuationdue to GI AEs. Vomiting was reported only in this one participant. No clear pattern of differences between men and women were observed for GI adverse events, as shown in 5Table 13 below, or any other type of adverse events, as shown in Table 14 below (N =number of participants, % = percentage of participants having an AE, and E = number of events). o a general type of adverse event (e.g.,(e.g., diarrhea, which is a specific type of gastrointestinal disorder). 10 Table 13: Adverse event reporting for women and men (total across 3 petrelintide cohorts and placebo) for selected System Organ Classes and Preferred Terms Table 14: Adverse event reporting for women and men (total across 3 petrelintide cohorts15 and placebo) for System Organ Classes 110 208 Summary of results Example 4 Post hoc analysis of the phase 1 clinical trial shown in Example 3. Analysis was carried out to determine the effects by sex of once-weekly subcutaneous petrelintide at doses of 2.4 mg,5 4.8 mg and 9.0 mg compared to pooled placebo. Figure 8 demonstrates that the greatesttreatment response was seen in female participants across all doses of petrelintide. Figure 8 further shows that, at petrelintide doses of 4.8 mg and 9.0 mg, the two largest reductions inbaseline body weight were in women.10 The results in Table 12 show the effect of petrelintide on body weight and waistcircumference for men and women. A greater reduction in both body weight and waist circumference is seen for women, compared to men, across all petrelintide dosages. Women saw a reduction in body weight of 7.0 %, 12.6 % and 14.6 % compared to 4.4 %, 7.1% and 6.8% for men at doses of 2.4 mg, 4.8 mg and 9.0 mg of petrelintide, respectively. The same15 trend was seen in waist circumference. Women saw a reduction in waist circumference of 12.5 cm, 13 cm and 14.5 cm compared to 3.5 cm, 5 cm, and 5.9 cm for men at doses of 2.4mg, 4.8 mg and 9.0 mg of petrelintide, respectively. We note that in each cohort only 2 or 3 participants were female (out of a total of 12 20 participants) and as a result were underrepresented. Despite this, the results shown in Table 111 208 12 demonstrate that petrelintide had a greater effect on reduction of body weight and waist circumference in women, compared to men. Table 13 shows the reporting of adverse events for men and women. The results shown in5 Table 13 do not indicate a clear pattern of differences of adverse events between men andwomen. Overall, the combined results shown in Figure 8 and Tables 12 and 13 demonstrate agreater reduction in body weight and waist circumference for women compared to men, 10 without an accompanying effect on the incidence of adverse events. Hence, petrelintide treatment resulted in clinically relevant reductions in body weight and waist circumference. Women showed greater treatment response, with a retained favourable tolerability profile. All publications mentioned in the above specification are herein incorporated by reference. 15 Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes 20 for carrying out the invention which are obvious to those skilled in biochemistry, molecular biology or related fields are intended to be within the scope of the following aspects. The present application claims priority from the following European patent applications: European patent application number EP24183571.9; 25 European patent application number EP24210314.1; and European patent application number EP25179842.7, which are incorporated by reference herein in their entirety. 112 208 NUMBERED CLAUSES The invention is described in the following numbered clauses: 51. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprising10 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg or more. 2. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to15 overweight, obesity or diabetes in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 3. A method of treating a disease linked to overweight, obesity or diabetes in a subject,20 the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 4. The method of any one of the preceding clauses, wherein the disease linked tooverweight, obesity or to diabetes is selected from the group consisting of obesity-linked25 inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity- induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, e-diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic30 dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholicsteatohepatitis (NASH), kidney failure, arteriosclerosis, macrovascular disease,microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease and stroke.35 5. A method of treating overweight in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 113 208 6. A method of treating overweight in the presence of at least one weight-relatedcomorbid condition in a subject, the method comprising administering petrelintide or apharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more 5 than about 2.4 mg. 7. A method of treating obesity in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 10 8. A method of treating morbid obesity in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg.15 9. A method of treating diabetes in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 10. A method of reducing body weight, reducing excess body weight, inhibiting weight20 gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg.25 11. A method of reducing body weight in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at adose of more than about 2.4 mg.12. A method of reducing excess body weight in a subject, the method comprising30 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 13. A method of inhibiting weight gain in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at35 a dose of more than about 2.4 mg. 114 208 14. A method maintaining weight reduction long term in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 515. A method of reducing food intake in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than about 2.4 mg. 16. A method of reducing appetite in a subject, the method comprising administering10 petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly ata dose of more than about 2.4 mg. 17. A method of increasing satiety in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at15 a dose of more than about 2.4 mg. 18. A method of promoting weight loss in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly ata dose of more than about 2.4 mg. 20 19. The method of any one of the preceding clauses, wherein the subject is overweight,overweight and has at least one weight-related comorbid condition, obese or morbidlyobese.25 20. The method of any one of the preceding clauses, wherein the subject is overweight.21. The method of any one of the preceding clauses, wherein the subject is overweightand has at least one weight-related comorbid condition.30 22. The method of any one of the preceding clauses, wherein the subject is obese.23. The method of any one of the preceding clauses, wherein the subject is morbidlyobese.35 24. The method of any one of the preceding clauses, wherein the subject has a BMI of25.0 kg / m2to 29.9 kg / m2corresponding to overweight. 115 208 25. The method of any one of the preceding clauses, wherein the subject has an initialBMI of 27 kg / m2or greater (overweight) in the presence of at least one weight-related comorbid condition. 526. The method of any one of the preceding clauses, wherein the subject has a BMI of30.0 kg / m2 to 39.9 kg / m2 corresponding to obese.27. The method of any one of the preceding clauses, wherein the subject has a BMI of40.0 kg / m2 or higher corresponding to morbidly obese.10 28. The method of any one of clauses 10 to 26, wherein the method is a non-therapeuticmethod. 29. The method of clause 28, wherein the subject is a healthy weight.15 30. The method of clause 28, wherein the subject is overweight.31. The method of clause 28, wherein the subject has a BMI of 18.5 kg / m2 to 24.9 kg / m2corresponding to healthy weight. 20 32. The method of clause 28, wherein the subject has a BMI of 25.0 kg / m2 to 29.9 kg / m2corresponding to overweight. 33. The method of any one of the preceding clauses, wherein the dose is about 2.5 mg25 or more, about 2.6 mg or more, about 2.7 mg or more, about 2.8 mg or more, about 2.9 mgor more, about 3.0 mg or more, about 3.1 mg or more, about 3.2 mg or more, about 3.3 mgor more, about 3.4 mg or more, about 3.5 mg or more, about 3.6 mg or more, about 3.7 mgor more, about 3.8 mg or more, about 3.9 mg or more, about 4.0 mg or more, about 4.1 mgor more, about 4.2 mg or more, about 4.3 mg or more, about 4.4 mg or more, about 4.5 mg30 or more, about 4.6 mg or more, about 4.7 mg or more, about 4.8 mg or more, about 4.9 mgor more, about 5.0 mg or more, about 5.5 mg or more, about 6.0 mg or more, about 6.5 mgor more, about 7.0 mg or more, about 7.5 mg or more, about 8.0 mg or more, about 8.5 mg or more, or about 9.0 mg or more.35 34. The method of any one of clauses 1 to 33, wherein the dose is more than about 2.5mg, more than about 2.6 mg, more than about 2.7 mg, more than about 2.8 mg, more thanabout 2.9 mg, more than about 3.0 mg, more than about 3.1 mg, more than about 3.2 mg,116 208 more than about 3.3 mg, more than about 3.4 mg, more than about 3.5 mg, more than about3.6 mg, more than about 3.7 mg, more than about 3.8 mg, more than about 3.9 mg, morethan about 4.0 mg, more than about 4.1 mg, more than about 4.2 mg, more than about 4.3mg, more than about 4.4 mg, more than about 4.5 mg, more than about 4.6 mg, more than5 about 4.7 mg, more than about 4.8 mg, more than about 4.9 mg, more than about 5.0 mg,more than about 5.5 mg, more than about 6.0 mg, more than about 6.5 mg, more than about7.0 mg, more than about 7.5 mg, more than 8.0 mg, or more than about 8.5 mg. 35. The method of any one of the preceding clauses, wherein the dose is at most about10 10.0 mg. 36. The method of any one of clauses 1 to 34, wherein the dose is at most about 9.5 mg.37. The method of any one of clauses 1 to 34, wherein the dose is at most about 9.0 mg.15 38. The method of any one of clauses 1 to 32, wherein the dose isfrom about 2.5 mg to about 10.0 mg, from about 2.6 mg to about 10.0 mg, from about 2.7 mgto about 10.0 mg, from about 2.8 mg to about 10.0 mg, from about 2.8 mg to about 10.0 mg,from about 2.9 mg to about 10.0 mg, from about 3.0 mg to about 10.0 mg, from about 3.1 mg20 to about 10.0 mg, from about 3.2 mg to about 10.0 mg, from about 3.3 mg to about 10.0 mg,from about 3.4 mg to about 10.0 mg, from about 3.5 mg to about 10.0 mg, from about 3.6 mgto about 10.0 mg, from about 3.7 mg to about 10.0 mg, from about 3.8 mg to about 10.0 mg,from about 3.9 mg to about 10.0 mg, from about 4.0 mg to about 10.0 mg, from about 4.1 mgto about 10.0 mg, from about 4.2 mg to about 10.0 mg, from about 4.3 mg to about 10.0 mg,25 from about 4.4 mg to about 10.0 mg, from about 4.5 mg to about 10.0 mg, from about 4.6 mgto about 10.0 mg, from about 4.7 mg to about 10.0 mg, from about 4.8 mg to about 10.0 mg,from about 4.9 mg to about 10.0 mg, from about 5.0 mg to about 10.0 mg, from about 5.5 mgto about 10.0 mg, from about 6.0 mg to about 10.0 mg, from about 7.0 mg to about 10.0 mg,from about 7.5 mg to about 10.0 mg, from about 8.0 mg to about 10.0 mg, from about 8.5 mg30 to about 10.0 mg, from about 9.0 mg to about 10.0 mg, from about 2.4 mg to about 9.0 mg, from about 2.5 mg to about 9.0 mg, from about 2.6 mg toabout 9.0 mg, from about 2.7 mg to about 9.0 mg, from about 2.8 mg to about 9.0 mg, fromabout 2.8 mg to about 9.0 mg, from about 2.9 mg to about 9.0 mg, from about 3.0 mg toabout 9.0 mg, from about 3.1 mg to about 9.0 mg, from about 3.2 mg to about 9.0 mg, from35 about 3.3 mg to about 9.0 mg, from about 3.4 mg to about 9.0 mg, from about 3.5 mg toabout 9.0 mg, from about 3.6 mg to about 9.0 mg, from about 3.7 mg to about 9.0 mg, fromabout 3.8 mg to about 9.0 mg, from about 3.9 mg to about 9.0 mg, from about 4.0 mg to117 208 about 9.0 mg, from about 4.1 mg to about 9.0 mg, from about 4.2 mg to about 9.0 mg, fromabout 4.3 mg to about 9.0 mg, from about 4.4 mg to about 9.0 mg, from about 4.5 mg toabout 9.0 mg, from about 4.6 mg to about 9.0 mg, from about 4.7 mg to about 9.0 mg, fromabout 4.8 mg to about 9.0 mg, from about 4.9 mg to about 9.0 mg, from about 5.0 mg to5 about 9.0 mg, from about 5.5 mg to about 9.0 mg, from about 6.0 mg to about 9.0 mg, fromabout 6.1 mg to about 9.0 mg, from about 6.5 mg to about 9.0 mg, from about 7.0 mg to about 9.0 mg, from about 7.5 mg to about 9.0 mg, from about 8.0 mg to about 9.0 mg, orfrom about 8.5 mg to about 9.0 mg.10 39. The method of any one of clauses 1 to 32, wherein the dose ismore than about 2.4 mg up to about 10.0 mg, more than about 2.5 mg up to about 10.0 mg,more than about 2.6 mg up to about 10.0 mg, more than about 2.7 mg up to about 10.0 mg,more than about 2.8 mg up to about 10.0 mg, more than about 2.9 mg up to about 10.0 mg,more than about 3.0 mg up to about 10.0 mg, more than about 3.1 mg up to about 10.0 mg,15 more than about 3.2 mg up to about 10.0 mg, more than about 3.3 mg up to about 10.0 mg,more than about 3.4 mg up to about 10.0 mg, more than about 3.5 mg up to about 10.0 mg,more than about 3.6 mg up to about 10.0 mg, more than about 3.7 mg up to about 10.0 mg,more than about 3.8 mg up to about 10.0 mg, more than about 3.9 mg up to about 10.0 mg,more than about 4.0 mg up to about 10.0 mg, more than about 4.1 mg up to about 10.0 mg,20 more than about 4.2 mg up to about 10.0 mg, more than about 4.3 mg up to about 10.0 mg,more than about 4.4 mg up to about 10.0 mg, more than about 4.5 mg up to about 10.0 mg,more than about 4.7 mg up to about 10.0 mg, more than about 4.8 mg up to about 10.0 mg,more than about 4.9 mg up to about 10.0 mg, more than about 5.0 mg up to about 10.0 mg,more than about 5.5 mg up to about 10.0 mg, more than about 6.0 mg up to about 10.0 mg,25 more than about 6.5 mg up to about 10.0 mg, more than about 7.0 mg up to about 10.0 mg,more than about 7.5 mg up to about 10.0 mg, more than about 8.0 mg up to about 10.0 mg,more than about 8.5 mg up to about 10.0 mg, more than about 9.0 mg up to about 10.0 mg,more than about 2.4 mg up to about 9.0 mg, more than about 2.5 mg up to about 9.0 mg,more than about 2.6 mg up to about 9.0 mg, more than about 2.7 mg up to about 9.0 mg,30 more than about 2.8 mg up to about 9.0 mg, more than about 2.9 mg up to about 9.0 mg,more than about 3.0 mg up to about 9.0 mg, more than about 3.1 mg up to about 9.0 mg,more than about 3.2 mg up to about 9.0 mg, more than about 3.3 mg up to about 9.0 mg,more than about 3.5 mg up to about 9.0 mg, more than about 3.6 mg up to about 9.0 mg,more than about 3.7 mg up to about 9.0 mg, more than about 3.8 mg up to about 9.0 mg,35 more than about 3.9 mg up to about 9.0 mg, more than about 4.0 mg up to about 9.0 mg,more than about 4.1 mg up to about 9.0 mg, more than about 4.2 mg up to about 9.0 mg,more than about 4.3 mg up to about 9.0 mg, more than about 4.4 mg up to about 9.0 mg,118 208 more than about 4.5 mg up to about 9.0 mg, more than about 4.6 mg up to about 9.0 mg,more than about 4.7 mg up to about 9.0 mg, more than about 4.8 mg up to about 9.0 mg,more than about 4.9 mg up to about 9.0 mg, more than about 5.0 mg up to about 9.0 mg,more than about 5.5 mg up to about 9.0 mg, more than about 6.0 mg up to about 9.0 mg,5 more than about 6.5 mg up to about 9.0 mg, more than about 7.0 mg up to about 9.0 mg,more than about 7.5 mg up to about 9.0 mg, or more than about 8.0 mg up to about 9.0 mg.40. The method of any one of clauses 1 to 32, wherein the dose is about 2.5 mg, about2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, about 3.2 10 mg, about 3.3 mg, about 3.4 mg, about 3.5 mg, about 3.6 mg, about 3.7 mg, about 3.8 mg, about 3.9 mg, about 4.0 mg, about 4.1 mg, about 4.2 mg, about 4.3 mg, about 4.4 mg, about 4.5 mg, about 4.6 mg, about 4.7 mg, about 4.8 mg, about 4.9 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 7.5 mg, about 8.0 mg, about 8.5 mg,or about 9.0 mg. 15 41. The method of any one of the preceding clauses, wherein the dose is about 4.8 mgor more. 42. The method of any one of the preceding clauses, wherein the dose is about 5.0 mg20 or more. 43. The method of any one of the preceding clauses, wherein the dose is about 6.0 mgor more.25 44. The method of any one of the preceding clauses, wherein the dose is about 7.0 mgor more. 45. The method of any one of the preceding clauses, wherein the dose is about 4.8 mg.30 46. The method of any one of the preceding clauses, wherein the dose is about 5.0 mg.47. The method of any one of the preceding clauses, wherein the dose is about 6.0 mg.48. The method of any one of the preceding clauses, wherein the dose is about 7.0 mg.35 49. The method of any one of the preceding clauses, wherein the dose is about 9.0 mg.119 208 50. The method of any one of the preceding clauses, wherein petrelintide or apharmaceutically acceptable salt thereof is administered subcutaneously, such as viasubcutaneous injection. 551. The method of any one of the preceding clauses, wherein petrelintide or apharmaceutically acceptable salt thereof is administered in the form of a composition further comprising one or more pharmaceutically acceptable excipients. 52. The method of clause 50, wherein the composition is in the form of a solution, such10 as an aqueous solution. 53. The method of any one of the preceding clauses, wherein the subject experiencesfewer or the same number of gastrointestinal adverse events compared to when the subject is administered petrelintide or a pharmaceutically acceptable salt thereof once weekly at a15 dose lower than 2.4 mg. 54. The method of any one of the preceding clauses, wherein the subject experiencesgastrointestinal adverse events of the same or lesser severity compared to when the subject is administered petrelintide or a pharmaceutically acceptable salt thereof once weekly at a20 dose lower than 2.4 mg. 55. The method of any one of the preceding clauses, wherein the subject does not sufferany severe gastrointestinal adverse events as a result of administration of petrelintide.25 56. The method of any one of clauses 52 to 54, wherein the gastrointestinal adverseevent is constipation. 57. The method of any one of clauses 52 to 54, wherein the gastrointestinal adverseevent is diarrhea. 30 58. The method of any one of the preceding clauses, wherein the subject is a humanfemale subject.59. The method of any one of the preceding clauses, wherein body weight of the subject35 is decreased by about 2% or more, about 2.5% or more, about 3.5% or more, about 4% ormore, about 4.5% or more, about 5% or more, about 5.5% or more, about 6% or more, about 6.5% or more, about 7% or more, about 7.5% or more, about 8% or more, about 8.5% or 120 208 more, about 9% or more, about 9.5% or more, or about 10% or more relative to their body weight at the start of treatment with petrelintide. 60. The method of any one of the preceding clauses, wherein the method comprises5 administering petrelintide or a pharmaceutically acceptable salt thereof in combination with a reduced calorie diet. 61. The method of clause 60, wherein the reduced calorie diet has an approximately 500kcal / day deficit. 10 62. The method of any one of the preceding clauses, wherein the method comprisesadministering petrelintide or a pharmaceutically acceptable salt thereof in combination with increased physical activity.15 63. The method of clauses 62, wherein increased physical activity is at least 150 minutesof physical activity per week. 64. The method of any one of the preceding clauses, wherein petrelintide or thepharmaceutically acceptable salt thereof is not administered with a GLP-1 / GLP-2 dual20 agonist. 65. The method of any one of the preceding clauses, wherein petrelintide or thepharmaceutically acceptable salt thereof is not administered with dapiglutide.25 66. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprising30 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of about 4.8 mg. 67. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to35 overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprising121 208 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of about 5.0 mg. 68. A method of treating overweight, overweight in the presence of at least one weight-5 related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about10 once weekly at a dose of about 6.0 mg. 69. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,15 inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of about 7.0 mg.20 70. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprising25 administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of about 9.0 mg. 71. Petrelintide or a pharmaceutically acceptable salt thereof for use in a method oftreating overweight, overweight in the presence of at least one weight-related comorbid 30 condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight, inhibiting weight gain,maintaining weight reduction long term, reducing food intake, reducing appetite, increasingsatiety or promoting weight loss, in a subject, the method comprising administeringpetrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at35 a dose of more than 2.4 mg. 122 208 72. Petrelintide or a pharmaceutically acceptable salt thereof for use in a method oftreating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically5 acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg.73. Petrelintide or a pharmaceutically acceptable salt thereof for use in a method oftreating overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a10 subject, the method comprising administering petrelintide or a pharmaceutically acceptablesalt thereof to the subject about once weekly at a dose of more than 2.4 mg.74. Petrelintide or a pharmaceutically acceptable salt thereof for use in a method oftreating obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or 15 diabetes in a subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg. 75. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 74, wherein the dose is from about 4.0 mg to about 10.0 mg.20 76. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 75, wherein the dose is more than about 4.6 mg to at most about 9.0mg.25 77. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 76, wherein the dose is from about 4.8 mg to about 9.0 mg.78. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 77, wherein the dose is 4.8 mg.30 79. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 77, wherein the dose is 5.0 mg.80. Petrelintide or a pharmaceutically acceptable salt thereof for use according to any35 one of clauses 71 to 77, wherein the dose is 6.0 mg.123 208 81. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 77, wherein the dose is 7.0 mg. 82. Petrelintide or a pharmaceutically acceptable salt thereof for use according to any5 one of clauses 71 to 77, wherein the dose is 9.0 mg.83. Petrelintide or a pharmaceutically acceptable salt thereof for use according to anyone of clauses 71 to 77, wherein the method is as defined in any one of clauses 1 to 70.10 84. Use of petrelintide or a pharmaceutically acceptable salt thereof in manufacture of amedicament for a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing15 appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject about once weekly at a dose of more than 2.4 mg. 85. The use according to clause 84, wherein the method is as defined in any one of20 clauses 1 to 70. 86. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked tooverweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,25 inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject.30 87. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the human female subject. 35 124 208 88. A method of treating a disease linked to overweight, obesity or diabetes in a humanfemale subject, the method comprising administering a non-incretin peptide hormone or apharmaceutically acceptable salt thereof to the human female subject.5 89. The method of any one of clauses 86 to 88, wherein the disease linked tooverweight, obesity or to diabetes is selected from the group consisting of obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity- induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin resistance syndrome, 10 impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholicsteatohepatitis (NASH), kidney failure, arteriosclerosis, macrovascular disease,microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a15 diabetic complication, coronary heart disease, peripheral artery disease and stroke. 90. A method of treating overweight in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the human female subject. 20 91. A method of treating overweight in the presence of at least one weight-relatedcomorbid condition in a human female subject, the method comprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human femalesubject. 25 92. A method of treating obesity in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the human female subject.30 93. A method of treating morbid obesity in a human female subject, the methodcomprising administering a non-incretin peptide hormone or a pharmaceutically acceptablesalt thereof to the human female subject. 94. A method of treating diabetes in a human female subject, the method comprising35 administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the human female subject. 125 208 95. A method of reducing body weight, reducing excess body weight, inhibiting weightgain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering a non-incretin peptide hormone or a pharmaceutically acceptable 5 salt thereof to the human female subject. 96. A method of reducing body weight in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject. 10 97. A method of reducing excess body weight in a human female subject, the methodcomprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject.15 98. A method of inhibiting weight gain in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject. 99. A method of maintaining weight reduction long term in a human female subject, the20 method comprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject. 100. A method of reducing food intake in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof25 to the human female subject. 101. A method of reducing appetite in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject. 30 102. A method of increasing satiety in a human female subject, the method comprisingadministering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject.35 103. A method of promoting weight loss in a human female subject, the methodcomprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject. 126 208 104. The method of any one of clauses 86 to 103, wherein the human female subject isoverweight, overweight and has at least one weight-related comorbid condition, obese ormorbidly obese. 5 105. The method of any one of clauses 86 to 104, wherein the human female subject isoverweight. 106. The method of any one of clauses 86 to 104, wherein the human female subject is10 overweight and has at least one weight-related comorbid condition. 107. The method of any one of clauses 86 to 104, wherein the human female subject isobese.15 108. The method of any one of clauses 86 to 104, wherein the human female subject ismorbidly obese. 109. The method of any one of clauses 86 to 104, wherein the human female subject hasa BMI of 25.0 kg / m2to 29.9 kg / m2corresponding to overweight. 20 110. The method of any one of clauses 86 to 104, wherein the human female subject hasa BMI of 30.0 kg / m2to 39.9 kg / m2corresponding to obese. 111. The method of any one of clauses 86 to 104, wherein the human female subject has25 a BMI of 40.0 kg / m2 or higher corresponding to morbidly obese.112. The method of any one of clauses 86 to 103, wherein the method is a non-therapeutic method.30 113. The method of clause 112, wherein the human female subject is a healthy weight.114. The method of clause 112, wherein the human female subject is overweight.115. The method of clause 112, wherein the human female subject has a BMI of 18.535 kg / m2 to 24.9 kg / m2 corresponding to healthy weight.127 208 116. The method of clause 112, wherein the human female subject has a BMI of 25.0kg / m2to 29.9 kg / m2corresponding to overweight. 117. The method of any one of clauses 86 to 116, wherein the method comprises5 administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the subject about once weekly. 118. The method of any one of clauses 86 to 117, wherein the non-incretin peptidehormone is an amylin analogue. 10 119. The method of any one of clauses 86 to 118, wherein the non-incretin peptidehormone is petrelintide. 120. The method of any one of clauses 86 to 119, wherein the method comprises15 administering the non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the subject at a dose of about 2.4 mg or more. 121. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone is about 2.5 mg or more, about 2.6 mg or more, about 2.7 mg or more,20 about 2.8 mg or more, about 2.9 mg or more, about 3.0 mg or more, about 3.1 mg or more,about 3.2 mg or more, about 3.3 mg or more, about 3.4 mg or more, about 3.5 mg or more,about 3.6 mg or more, about 3.7 mg or more, about 3.8 mg or more, about 3.9 mg or more,about 4.0 mg or more, about 4.1 mg or more, about 4.2 mg or more, about 4.3 mg or more,about 4.4 mg or more, about 4.5 mg or more, about 4.6 mg or more, about 4.7 mg or more,25 about 4.8 mg or more, about 4.9 mg or more, about 5.0 mg or more, about 5.5 mg or more,about 6.0 mg or more, about 6.5 mg or more, about 7.0 mg or more, about 7.5 mg or more, about 8.0 mg or more, about 8.5 mg or more, or about 9.0 mg or more. 122. The method of any one of clauses 86 to 120, wherein the dose of the non-incretin30 peptide hormone is more than about 2.4 mg, more than about 2.5 mg, more than about 2.6mg, more than about 2.7 mg, more than about 2.8 mg, more than about 2.9 mg, more thanabout 3.0 mg, more than about 3.1 mg, more than about 3.2 mg, more than about 3.3 mg,more than about 3.4 mg, more than about 3.5 mg, more than about 3.6 mg, more than about3.7 mg, more than about 3.8 mg, more than about 3.9 mg, more than about 4.0 mg, more35 than about 4.1 mg, more than about 4.2 mg, more than about 4.3 mg, more than about 4.4mg, more than about 4.5 mg, more than about 4.6 mg, more than about 4.7 mg, more thanabout 4.8 mg, more than about 4.9 mg, more than about 5.0 mg, more than about 5.5 mg,128 208 more than about 6.0 mg, more than about 6.5 mg, more than about 7.0 mg, more than about7.5 mg, more than 8.0 mg, or more than about 8.5 mg. 123. The method of any one of clauses 86 to 122, wherein the dose of the non-incretin5 peptide hormone or a pharmaceutically acceptable salt thereof is at most about 10.0 mg. 124. The method of any one of clauses 86 to 122, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is at most about 9.5 mg.10 125. The method of any one of clauses 86 to 122, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is at most about 9.0 mg.126. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is from about 2.4 mg to about15 10.0 mg, from about 2.5 mg to about 10.0 mg, from about 2.6 mg to about 10.0 mg, fromabout 2.7 mg to about 10.0 mg, from about 2.8 mg to about 10.0 mg, from about 2.8 mg toabout 10.0 mg, from about 2.9 mg to about 10.0 mg, from about 3.0 mg to about 10.0 mg,from about 3.1 mg to about 10.0 mg, from about 3.2 mg to about 10.0 mg, from about 3.3 mgto about 10.0 mg, from about 3.4 mg to about 10.0 mg, from about 3.5 mg to about 10.0 mg,20 from about 3.6 mg to about 10.0 mg, from about 3.7 mg to about 10.0 mg, from about 3.8 mgto about 10.0 mg, from about 3.9 mg to about 10.0 mg, from about 4.0 mg to about 10.0 mg,from about 4.1 mg to about 10.0 mg, from about 4.2 mg to about 10.0 mg, from about 4.3 mgto about 10.0 mg, from about 4.4 mg to about 10.0 mg, from about 4.5 mg to about 10.0 mg,from about 4.6 mg to about 10.0 mg, from about 4.7 mg to about 10.0 mg, from about 4.8 mg25 to about 10.0 mg, from about 4.9 mg to about 10.0 mg, from about 5.0 mg to about 10.0 mg,from about 5.5 mg to about 10.0 mg, from about 6.0 mg to about 10.0 mg, from about 7.0 mgto about 10.0 mg, from about 7.5 mg to about 10.0 mg, from about 8.0 mg to about 10.0 mg, from about 8.5 mg to about 10.0 mg, from about 9.0 mg to about 10.0 mg,from about 2.4 mg to about 9.0 mg, from about 2.5 mg to about 9.0 mg, from about 2.6 mg to30 about 9.0 mg, from about 2.7 mg to about 9.0 mg, from about 2.8 mg to about 9.0 mg, fromabout 2.8 mg to about 9.0 mg, from about 2.9 mg to about 9.0 mg, from about 3.0 mg toabout 9.0 mg, from about 3.1 mg to about 9.0 mg, from about 3.2 mg to about 9.0 mg, fromabout 3.3 mg to about 9.0 mg, from about 3.4 mg to about 9.0 mg, from about 3.5 mg toabout 9.0 mg, from about 3.6 mg to about 9.0 mg, from about 3.7 mg to about 9.0 mg, from35 about 3.8 mg to about 9.0 mg, from about 3.9 mg to about 9.0 mg, from about 4.0 mg toabout 9.0 mg, from about 4.1 mg to about 9.0 mg, from about 4.2 mg to about 9.0 mg, fromabout 4.3 mg to about 9.0 mg, from about 4.4 mg to about 9.0 mg, from about 4.5 mg to129 208 about 9.0 mg, from about 4.6 mg to about 9.0 mg, from about 4.7 mg to about 9.0 mg, fromabout 4.8 mg to about 9.0 mg, from about 4.9 mg to about 9.0 mg, from about 5.0 mg toabout 9.0 mg, from about 5.5 mg to about 9.0 mg, from about 6.0 mg to about 9.0 mg, fromabout 6.1 mg to about 9.0 mg, from about 6.5 mg to about 9.0 mg, from about 7.0 mg to 5 about 9.0 mg, from about 7.5 mg to about 9.0 mg, from about 8.0 mg to about 9.0 mg, or from about 8.5 mg to about 9.0 mg. 127. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is more than about 2.4 mg up10 to about 10.0 mg, more than about 2.5 mg up to about 10.0 mg, more than about 2.6 mg upto about 10.0 mg, more than about 2.7 mg up to about 10.0 mg, more than about 2.8 mg upto about 10.0 mg, more than about 2.9 mg up to about 10.0 mg, more than about 3.0 mg upto about 10.0 mg, more than about 3.1 mg up to about 10.0 mg, more than about 3.2 mg upto about 10.0 mg, more than about 3.3 mg up to about 10.0 mg, more than about 3.4 mg up15 to about 10.0 mg, more than about 3.5 mg up to about 10.0 mg, more than about 3.6 mg upto about 10.0 mg, more than about 3.7 mg up to about 10.0 mg, more than about 3.8 mg upto about 10.0 mg, more than about 3.9 mg up to about 10.0 mg, more than about 4.0 mg upto about 10.0 mg, more than about 4.1 mg up to about 10.0 mg, more than about 4.2 mg upto about 10.0 mg, more than about 4.3 mg up to about 10.0 mg, more than about 4.4 mg up20 to about 10.0 mg, more than about 4.5 mg up to about 10.0 mg, more than about 4.7 mg upto about 10.0 mg, more than about 4.8 mg up to about 10.0 mg, more than about 4.9 mg upto about 10.0 mg, more than about 5.0 mg up to about 10.0 mg, more than about 5.5 mg upto about 10.0 mg, more than about 6.0 mg up to about 10.0 mg, more than about 6.5 mg upto about 10.0 mg, more than about 7.0 mg up to about 10.0 mg, more than about 7.5 mg up25 to about 10.0 mg, more than about 8.0 mg up to about 10.0 mg, more than about 8.5 mg upto about 10.0 mg, more than about 9.0 mg up to about 10.0 mg,more than about 2.4 mg up to about 9.0 mg, more than about 2.5 mg up to about 9.0 mg,more than about 2.6 mg up to about 9.0 mg, more than about 2.7 mg up to about 9.0 mg,more than about 2.8 mg up to about 9.0 mg, more than about 2.9 mg up to about 9.0 mg,30 more than about 3.0 mg up to about 9.0 mg, more than about 3.1 mg up to about 9.0 mg,more than about 3.2 mg up to about 9.0 mg, more than about 3.3 mg up to about 9.0 mg,more than about 3.5 mg up to about 9.0 mg, more than about 3.6 mg up to about 9.0 mg,more than about 3.7 mg up to about 9.0 mg, more than about 3.8 mg up to about 9.0 mg,more than about 3.9 mg up to about 9.0 mg, more than about 4.0 mg up to about 9.0 mg,35 more than about 4.1 mg up to about 9.0 mg, more than about 4.2 mg up to about 9.0 mg,more than about 4.3 mg up to about 9.0 mg, more than about 4.4 mg up to about 9.0 mg,more than about 4.5 mg up to about 9.0 mg, more than about 4.6 mg up to about 9.0 mg,130 208 more than about 4.7 mg up to about 9.0 mg, more than about 4.8 mg up to about 9.0 mg,more than about 4.9 mg up to about 9.0 mg, more than about 5.0 mg up to about 9.0 mg,more than about 5.5 mg up to about 9.0 mg, more than about 6.0 mg up to about 9.0 mg,more than about 6.5 mg up to about 9.0 mg, more than about 7.0 mg up to about 9.0 mg,5 more than about 7.5 mg up to about 9.0 mg, or more than about 8.0 mg up to about 9.0 mg.128. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, 10 about 3.2 mg, about 3.3 mg, about 3.4 mg, about 3.5 mg, about 3.6 mg, about 3.7 mg, about 3.8 mg, about 3.9 mg, about 4.0 mg, about 4.1 mg, about 4.2 mg, about 4.3 mg, about 4.4 mg, about 4.5 mg, about 4.6 mg, about 4.7 mg, about 4.8 mg, about 4.9 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 7.5 mg, about 8.0 mg, about8.5 mg, or about 9.0 mg.15 128. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 4.8 mg or more.129. The method of any one of clauses 86 to 120, wherein the dose of the non-incretin20 peptide hormone or a pharmaceutically acceptable salt thereof is about 5.0 mg or more.130. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 6.0 mg or more.25 131. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 7.0 mg or more.132. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 4.8 mg.30 133. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 5.0 mg.134. The method of any one of clauses 86 to 120, wherein the dose of the non-incretin35 peptide hormone or a pharmaceutically acceptable salt thereof is about 6.0 mg.131 208 135. The method of any one of clauses 86 to 120, wherein the dose of the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof is about 7.0 mg.136. The method of any one of clauses 86 to 120, wherein the dose of the non-incretin5 peptide hormone or a pharmaceutically acceptable salt thereof is about 9.0 mg.137. The method of any one of clauses 86 to 136, wherein the non-incretin peptidehormone or a pharmaceutically acceptable salt thereof is administered subcutaneously, such as via subcutaneous injection. 10 138. The method of any one of clauses 86 to 136, wherein the non-incretin peptidehormone or a pharmaceutically acceptable salt thereof is administered in the form of a composition further comprising one or more pharmaceutically acceptable excipients.15 139. The method of clause 138, wherein the composition is in the form of a solution, suchas an aqueous solution. 140. The method of any one of clauses 86 to 139, wherein the human female subjectexperiences fewer or the same number of gastrointestinal adverse events compared to a20 corresponding human male subject administered the non-incretin peptide hormone or apharmaceutically acceptable salt thereof. 141. The method of any one of clauses 86 to 140, wherein the human female subjectexperiences gastrointestinal adverse events of the same or lesser severity compared to a25 corresponding human male subject administered the non-incretin peptide hormone or apharmaceutically acceptable salt thereof. 142. The method of any one of clauses 86 to 141, wherein the human female subject doesnot suffer any severe gastrointestinal adverse events as a result of administration of the non-30 incretin peptide hormone or a pharmaceutically acceptable salt thereof.143. The method of any one of clauses 140 to 142, wherein the gastrointestinal adverse event is constipation.35 144. The method of any one of clauses 140 to 143, wherein the gastrointestinal adverseevent is diarrhea. 132 208 145. The method of any one of clauses 86 to 144, wherein body weight of the humanfemale subject is decreased by about 2% or more, about 2.5% or more, about 3.5% or more, about 4% or more, about 4.5% or more, about 5% or more, about 5.5% or more, about 6% or more, about 6.5% or more, about 7% or more, about 7.5% or more, about 8% or more, 5 about 8.5% or more, about 9% or more, about 9.5% or more, or about 10% or more relative to their body weight at the start of treatment with the non-incretin peptide hormone. 146. The method of any one of clauses 86 to 145, wherein body weight of the humanfemale subject is decreased proportionally more than the body weight of a corresponding10 human male subject administered the non-incretin peptide hormone or a pharmaceuticallyacceptable salt thereof. 147. The method of clause 146, wherein body weight of the human female subject isdecreased by at least 1% more than the body weight of the human male subject15 administered the non-incretin peptide hormone, such as by at least about 1.5% more, at least about 2% more, at least about 2.5% more, at least about 3% more, at least about 3.5% more, at least about 4% more, at least about 5% more, at least about 6% more, at leastabout 7% more, or at least about 8% more.20 148. The method of any one of clauses 86 to 147, wherein the method comprisesadministering the non-incretin peptide hormone or a pharmaceutically acceptable salt thereofin combination with a reduced calorie diet. 149. The method of any one of clauses 86 to 148, wherein the method comprises25 administering the non-incretin peptide hormone or a pharmaceutically acceptable salt thereofin combination with increased physical activity. 150. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to30 overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducingappetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof onceweekly to the human female subject.35 151. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to133 208 overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof once5 weekly to the human female subject at a dose of about 4.8 mg.152. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked tooverweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,10 inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof onceweekly to the human female subject at a dose of about 5.0 mg.15 153. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked tooverweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducingappetite, increasing satiety or promoting weight loss, in a human female subject, the method20 comprising administering petrelintide or a pharmaceutically acceptable salt thereof onceweekly to the human female subject at a dose of about 6.0 mg.154. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to25 overweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the method comprising administering petrelintide or a pharmaceutically acceptable salt thereof onceweekly to the human female subject at a dose of about 7.0 mg.30 155. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked tooverweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing35 appetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering petrelintide or a pharmaceutically acceptable salt thereof onceweekly to the human female subject at a dose of about 9.0 mg. 134 208 156. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, 5obesity or diabetes, or of reducing body weight, reducing excess body weight, inhibitingweight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the methodcomprising administering the non-incretin peptide hormone or a pharmaceutically acceptablesalt thereof to the human female subject.10 157. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-relatedcomorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a human female subject, the method comprising administering the15 non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the subject.158. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for usein a method of treating overweight in the presence of at least one weight-related comorbidcondition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or20 diabetes in a human female subject, the method comprising administering the non-incretinpeptide hormone or a pharmaceutically acceptable salt thereof to the subject.159. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for usein a method of treating overweight in the presence of at least one weight-related comorbid25 condition, obesity or morbid obesity in a human female subject, the method comprisingadministering the non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the subject. 160. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for use30 according to any one of clauses 156 to 159, wherein the non-incretin peptide hormone isadministered to the human female subject about once weekly. 161. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for useaccording to any one of clauses 156 to 160, wherein the non-incretin peptide hormone is35 petrelintide. 135 208 162. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for useaccording to any one of clauses 156 to 161, wherein the method is as defined in any one ofclauses 86 to 155.5 163. Use of a non-incretin peptide hormone or a pharmaceutically acceptable salt thereofin manufacture of a medicament for a method of treating overweight, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes, or of reducing bodyweight, reducing excess body weight, inhibiting weight gain, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprising10 administering the non-incretin peptide hormone or a pharmaceutically acceptable salt thereofto the subject. 164. The use according to clause 163, wherein the method is as defined in any one ofclauses 86 to 155.136 208 NUMBERED ASPECTS The invention is also described in the following numbered aspects: 1. A method of treating obesity, morbid obesity, diabetes, or a disease linked to obesity5 or diabetes, or of reducing body weight, inhibiting weight gain, reducing food intake, reducingappetite or promoting weight loss, in a subject, the method comprising administering petrelintide to the subject once weekly at a dose of 2.4 mg or more. 2. A method of treating obesity, morbid obesity, diabetes, or a disease linked to obesity10 or diabetes in a subject, the method comprising administering petrelintide to the subject onceweekly at a dose of 2.4 mg or more. 3. The method of aspect 1 or aspect 2, wherein the disease linked to obesity or todiabetes is selected from the group consisting of: obesity-linked inflammation, obesity-linked15 gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity- linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, disease, pre-diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-20 alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), kidney failure,arteriosclerosis, macrovascular disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complicat...

Claims

208 CLAIMS 1. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked tooverweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,5 inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a subject, the method comprisingadministering petrelintide or a pharmaceutically acceptable salt thereof to the subject aboutonce weekly at a dose of more than about 2.4 mg.10 2. Petrelintide or a pharmaceutically acceptable salt thereof for use in a method oftreating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight, obesity or diabetes in a subject, the method comprising administering petrelintide to the subject onceweekly at a dose of more than 2.4 mg. 15 3. The method of claim 1, or petrelintide or a pharmaceutically acceptable salt thereoffor use of claim 2, wherein the disease linked to overweight, obesity or diabetes is selected from the group consisting of obesity-linked inflammation, obesity-linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory20 problems, degeneration of cartilage, osteoarthritis, infertility, - diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholicfatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), kidney failure,25 arteriosclerosis, macrovascular disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heart disease, peripheral artery disease and stroke.

4. The method of claim 1 or claim 3, or petrelintide or a pharmaceutically acceptable30 salt thereof for use of claim 2 or claim 3, wherein the dose is from about 4.0 mg to about10.0 mg.

5. The method of any one of claims 1, 3 and 4, or petrelintide or a pharmaceuticallyacceptable salt thereof for use of any one of claims 2 to 4, wherein the dose is more than35 about 4.6 mg to at most about 9.0 mg. 141208 6. The method of any one of claims 1, 3 to 5, or petrelintide or a pharmaceuticallyacceptable salt thereof for use of any one of claims 2 to 5, wherein the dose is from about4.8 mg to about 9.0 mg.

57. The method of any one of claims 1 and 3 to 6, or petrelintide or a pharmaceuticallyacceptable salt thereof for use of any one of claims 2 to 6, wherein the dose is about 4.8 mg,about 5.0 mg, about 6.0 mg, about 7.0 mg or about 9.0 mg.

8. The method of any one of the preceding claims, wherein the subject experiences10 fewer or the same number of gastrointestinal adverse events compared to when the subject is administered petrelintide once weekly at a dose lower than 2.4 mg.

9. The method of any one of the preceding claims, wherein the subject experiencesgastrointestinal adverse events of the same or lesser severity compared to when the subject15 is administered petrelintide once weekly at a dose lower than 2.4 mg.

10. The method of any one of the preceding claims, wherein the subject does not sufferany severe gastrointestinal adverse events as a result of administration of petrelintide.20 11. The method of any one of claims 8 to 10, wherein the gastrointestinal adverse eventis diarrhea or constipation.

12. The method of any one of the preceding claims, wherein body weight of the subject isdecreased by about 2% or more, about 2.5% or more, about 3% or more, about 3.5% or 25 more, about 4% or more, about 4.5% or more, about 5% or more, about 5.5% or more, about 6% or more, about 6.5% or more, about 7% or more, about 7.5% or more, about 8% or more, about 8.5% or more, about 9% or more, about 9.5% or more, or about 10% or more relative to their body weight at the start of treatment with petrelintide.30 13. A method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked tooverweight, obesity or diabetes, or of reducing body weight, reducing excess body weight,inhibiting weight gain, maintaining weight reduction long term, reducing food intake, reducing appetite, increasing satiety or promoting weight loss, in a human female subject, the method35 comprising administering a non-incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject. 142208 14. A non-incretin peptide hormone or a pharmaceutically acceptable salt thereof for usein a method of treating overweight, overweight in the presence of at least one weight-related comorbid condition, obesity, morbid obesity, diabetes, or a disease linked to overweight,obesity or diabetes in a human female subject, the method comprising administering a non- 5 incretin peptide hormone or a pharmaceutically acceptable salt thereof to the human female subject.

15. The method of claim 13 or the non-incretin peptide hormone or a pharmaceuticallyacceptable salt thereof for use of claim 14, wherein the disease linked to overweight, obesity10 or diabetes is selected from the group consisting of: obesity-linked inflammation, obesity- linked gallbladder disease, obesity-induced type 2 diabetes, obesity-induced sleep apnea, obesity-linked respiratory problems, degeneration of cartilage, osteoarthritis, infertility, -diabetes, insulin resistance syndrome, impaired glucose tolerance (IGT), disease states associated with elevated blood glucose levels, metabolic disease, 15 metabolic syndrome, hyperglycemia, hypertension, atherogenic dyslipidemia, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH),kidney failure, arteriosclerosis, macrovascular disease, microvascular disease, diabetic heart disease, diabetic cardiomyopathy, heart failure as a diabetic complication, coronary heartdisease, peripheral artery disease and stroke. 20 16. The method of claim 13 or claim 15, or the non-incretin peptide hormone or apharmaceutically acceptable salt thereof for use of claim 14 or claim 15, wherein the methodcomprises administering the non-incretin peptide hormone or a pharmaceutically acceptablesalt thereof to the human female subject at a dose of about 2.4 mg or more, a dose of more25 than about 2.4 mg, a dose of about 4.8 mg or more, a dose of about 6.0 mg or more, a dose of about 4.8 mg, a dose of about 5.0 mg, a dose of about 6.0 mg, a dose of about 7.0 mg, ora dose of about 9.0 mg.

17. The method of any one of claims 13, 15 and 16, or the non-incretin peptide hormone30 or a pharmaceutically acceptable salt thereof for use of any one of claims 14 to 16, whereinthe method comprises administering the non-incretin peptide hormone to the subject aboutonce weekly.

18. The method of any one of claims 13 and 15 to 17, or the non-incretin peptide35 hormone or a pharmaceutically acceptable salt thereof for use of any one of claims 14 to 17,wherein the non-incretin peptide hormone is an amylin analogue. 143208 19. The method of any one of claims 13 and 15 to 18, or the non-incretin peptidehormone or a pharmaceutically acceptable salt thereof for use of any one of claims 14 to 18,wherein the non-incretin peptide hormone is petrelintide.5 20. The method of any one of claims 1, 3 to 13, and 15 to 19, wherein the method is anon-therapeutic method. 144

Images